,pmid,rpsid,pmidlink,components_type,rna_id,rna_id_interface,rnas,rna_length,rna_sequence,rna_classification,source,protein_sequence,protein_name,protein_region,protein_modification,protein_sequence_length,Uniprot ID,mark,link,IDR,low complexity domain,In_vitrovivo,solute_concentration,salt_concentration,buffer,temperature,incubation_time,other_requirement,detection_method,morphology,description
0,PMID: 26351690,RNAPS0000159,https://pubmed.ncbi.nlm.nih.gov/26351690,RNAs + protein,-,-,Caenorhabditis elegans rRNA,50nt,-,rRNA,Caenorhabditis elegans,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib-1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,5.5 µM [fib1];|5 µM rRNA,250 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Microscopy,liquid,"RNA specificity did not increase the magnitude of phase separation. We found quantitatively similar results with an in vitro-transcribed segment of C. elegans rRNA that is a direct substrate of FIB-1. Moreover, in addition to shifting the phase boundary, RNA accelerated droplet coarsening."
1,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05 % (w/w) tRNA,4 mM MgCl2,"50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,> 50 min,other_molecular:2.25 mM ATP,Turbidity measurement,liquid,"Turbidity persisted in controls lacking kinase (red trace, Fig. 3b) and in those with adenosine diphosphate (ADP) substituted for ATP (blue trace, Fig. 3b). We also found that PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution (Supplementary Fig. 10) and tRNA/RRASLRRASL coacervates in buffered solution (Supplementary Fig. 11)."
2,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05 % (w/w) tRNA,4 mM MgCl2,"50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,≤ 60 min,"other_molecular:0.005 mg/ml PKA,2.25 mM ATP",Turbidity measurement,solute,"Turbidity persisted in controls lacking kinase (red trace, Fig. 3b) and in those with adenosine diphosphate (ADP) substituted for ATP (blue trace, Fig. 3b). We also found that PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution (Supplementary Fig. 10) and tRNA/RRASLRRASL coacervates in buffered solution (Supplementary Fig. 11)."
3,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05 % (w/w) tRNA,4 mM MgCl2,"50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,≤ 60 min,"other_molecular:0.005 mg/ml PKA,2.25 mM ADP",Turbidity measurement,liquid,"Turbidity persisted in controls lacking kinase (red trace, Fig. 3b) and in those with adenosine diphosphate (ADP) substituted for ATP (blue trace, Fig. 3b). We also found that PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution (Supplementary Fig. 10) and tRNA/RRASLRRASL coacervates in buffered solution (Supplementary Fig. 11)."
4,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.15% (w/w) tRNA,"4 mM MgCl2, 1 mM MnCl2","50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,> 20 min,other_molecular:0.040 µM LPP,Turbidity measurement,liquid,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
5,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.15% (w/w) tRNA,"4 mM MgCl2, 1 mM MnCl2","50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,> 5 min,-,Turbidity measurement,solute,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
6,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.15% (w/w) tRNA,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,≤ 80 min.,other_molecular:0.040 µM LPP,Turbidity measurement,solute,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
7,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) tRNA,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 2 min,other_molecular:2.25 mM ATP,"Confocal microscopy,Fluorescence microscopy",liquid,These coacervates were similar in size to the polyU coacervates (1.8 ± 0.6 µM). We conclude that coacervation in these systems is not RNA sequence dependent and is largely driven by electrostatic attraction between the negatively charged RNAs and the positively charged peptides.
8,PMID: 26836305,RNAPS0000162,https://pubmed.ncbi.nlm.nih.gov/26836305,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=174aa|residues=121-294
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,△N,-,174aa(121-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[121-259],-,In vitro,0-50 µM [NPM1△N];|50 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 5 min,-,Turbidity measurement,solute,"Neither of these truncated constructs (NPM1 N240, NPM1△N) experienced phase separation in the presence of rRNA, confirming that multivalent display of the NBD is required for the co-localization of rRNA with NPM1 within liquid-like droplets."
9,PMID: 26836305,RNAPS0000162,https://pubmed.ncbi.nlm.nih.gov/26836305,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=240aa|residues=1-240
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG",NPM1,N240,-,240aa(1-240),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-240],-,In vitro,0-50 µM [NPM1 N240];|50 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 5 min,-,Turbidity measurement,solute,"Neither of these truncated constructs (NPM1 N240, NPM1△N) experienced phase separation in the presence of rRNA, confirming that multivalent display of the NBD is required for the co-localization of rRNA with NPM1 within liquid-like droplets."
10,PMID: 26836305,RNAPS0000162,https://pubmed.ncbi.nlm.nih.gov/26836305,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=294aa|residues=1-294
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,-,-,294aa(1-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,10-50 µM [NPM1];|50 µg/mL rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 5 min,-,"Turbidity measurement,Fluorescence microscopy",liquid,"We tested and confirmed the ability of full length NPM1 (N294) to phase separate with either wheat germ rRNA or rpL5 using light scattering and fluorescence microscopy. Binary mixtures of NPM1 with either rpL5 or rRNA formed droplets that increased in size over time; those with rpL5 fused more rapidly and were larger in size than those with rRNA. Furthermore, droplets of NPM1 with rpL5 formed at ~5-fold lower concentrations of both components than were required for phase separation with N130 and rpL5 due to the higher valency of acidic tracts within the full-length protein."
11,PMID: 27212236,RNAPS0000164,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=100aa|residues=1-100
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGS",fib1,△C,-,100aa(1-100),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-100],[8-100],In vitro,1 µM [fib1△C];|5 µg/ml rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,liquid,"The R/G domain (FIB1△C) is sufficient to form liquid-like droplets in vitro, while the MD alone (FIB1△N) is unable to form droplets in vitro. Interestingly, FIB1△C can phase separate into liquid-like droplets in vitro, even in the absence of RNA. By contrast, full-length FIB1 requires rRNA; however, this may be a non-specific consequence of the polyanionic nature of rRNA since heparin can also drive phase separation of full-length FIB1. FIB1△C droplets also exhibit faster dynamics than full-length FIB1."
12,PMID: 27212236,RNAPS0000164,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=252aa|residues=101-352
PRGGRGGAGGMRGGKTVVVEPHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGA
GSIEYRVWNPFRSKLAASIMGGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYA
VEFSHRSGRDLLGVAKKRPNVVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALN
AQNFLRNGGHAVISIKANCIDSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVV
VAVYRPVKGKKV",fib1,-,-,252aa(101-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[101-115],[101-114],In vitro,1 µM [fib1△N];|5 µg/ml rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,solute,"The R/G domain (FIB1△C) is sufficient to form liquid-like droplets in vitro, while the MD alone (FIB1△N) is unable to form droplets in vitro. Interestingly, FIB1△C can phase separate into liquid-like droplets in vitro, even in the absence of RNA. By contrast, full-length FIB1 requires rRNA; however, this may be a non-specific consequence of the polyanionic nature of rRNA since heparin can also drive phase separation of full-length FIB1. FIB1△C droplets also exhibit faster dynamics than full-length FIB1."
13,PMID: 27212236,RNAPS0000164,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,0.25-1 µM [fib1];|5 µg/ml rRNA,50-250 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,≤ 2 h,-,FRAP,"liquid, solid","FIB1 can phase separate in vitro under near physiological protein and salt concentrations, giving rise to condensed liquid-phase droplets that are ~50-fold more concentrated with protein than the surrounding dilute phase. FIB1 droplets typically take roughly a hundred times longer than NPM1 droplets of comparable size to coalesce and relax into a single larger sphere. FIB1 FRAP dynamics are strongly impacted by the droplet age. By 2 hr, these droplets become increasingly solid-like with time, potentially due to the formation of fibers. Liquid-like FIB1 droplets evolve into sticky gel structures over a 2-hr time period."
14,PMID: 27212236,RNAPS0000165,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=175aa|residues=120-294
EEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDD
DFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPK
GPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,△N,-,175aa(120-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[120-259],-,In vitro,5 µM [NPM1△N];|100 µg/mL rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,solute,"Neither mutants of NPM1 is able to form droplets in vitro, consistent with phase separation of NPM1 requiring the oligomerization of NPM1 into multivalent pentamers that can bind to rRNA. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles."
15,PMID: 27212236,RNAPS0000165,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=240aa|residues=1-240
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG",NPM1,N240,-,240aa(1-240),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-240],-,In vitro,5 µM [NPM1△C];|100 µg/mL rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,solute,"Neither mutants of NPM1 is able to form droplets in vitro, consistent with phase separation of NPM1 requiring the oligomerization of NPM1 into multivalent pentamers that can bind to rRNA. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles."
16,PMID: 27212236,RNAPS0000165,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=294aa|residues=1-294
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,-,-,294aa(1-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,2-8 µM [NPM1];|100 µg/ml rRNA,100-250 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,≤ 2 h,-,FRAP,"solute, liquid","NPM1 has also recently been demonstrated to undergo phase separation into liquid-like droplets. However, at 150 mM NaCl, NPM1 requires significantly higher concentrations of protein and rRNA. Moreover, phase separation of NPM1 required rRNA and cannot be induced by the addition of heparin or poly-U50. After 30 min of initiating phase separation, we find that NPM1 always exhibits a near complete recovery, even for droplets that have been sitting for several hours."
17,PMID: 27545621,RNAPS0000167,https://pubmed.ncbi.nlm.nih.gov/27545621,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=148aa|residues=267-414
NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA
QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG
SASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,CTD,-,148aa(267-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[267-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,3-90 µg/mL RNA;|20 µM [TDP-43 CTD],-,"20 mM MES (pH 6.1), 1M DTT",22˚C,-,-,Turbidity measurement,liquid,"TDP-43 CTD LLPS peaks in the presence of increasing amounts of RNA, possibly due to saturation of the protein-RNA interactions."
18,PMID: 27545621,RNAPS0000167,https://pubmed.ncbi.nlm.nih.gov/27545621,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=148aa|residues=267-414
NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA
QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG
SASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,CTD,-,148aa(267-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[267-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,3 µg/mL RNA;|20 µM [TDP-43 CTD],-,20 mM MES (pH 6.1),22˚C,-,-,"Differential interference contrast microscopy,FRAP",liquid,"At low salt concentration (0 M NaCl), 20 uM CTD remains monomeric. However, upon addition of 150 mM NaCl, the domain rapidly undergoes LLPS. These assemblies appear as dynamic, high protein concentration liquid droplets that flow and fuse and show effectively complete fluorescence recovery after photobleaching (FRAP), highlighting their liquid-like character. Addition of yeast RNA as low as 3 ug/mL resulted in phase separation. As previously observed for full-length FUS aggregation and phase separation, TDP-43 CTD LLPS peaks in the presence of increasing amounts of RNA, possibly due to saturation of the protein-RNA interactions."
19,PMID: 27594427,RNAPS0000170,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans mRNA,-,-,mRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,10 ng/µl mRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"In contrast, addition of total mRNA significantly increased both the number of PGL-3 drops and fraction of total PGL-3 that concentrated within these drops. Therefore, we conclude that mRNA rather than rRNA drives the formation of PGL-3 drops."
20,PMID: 27594427,RNAPS0000170,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans mRNA,-,-,mRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693|mutation=R634L,R638G,R650L,R661G,R665G,R690G
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGLGGDGGGRGAYGGDRGLGGSGDGSRGY
GGGDGGGRGSYGEGSRGYQGGRAGFFGGSGGGS",pgl-3,-,"protein_mutation:R634L,R638G,R650L,R661G,R665G,R690G",693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[1-6],[51-70],[107-107],[112-134],[149-157],[181-194],[219-254],[279-287],[342-353],[368-381],[438-473],[484-487],[516-533],[551-594],[626-674],[683-693]",-,In vitro,10 ng/µl mRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,solute,"Total mRNA failed to promote assembly of drops at physiological protein concentrations of a PGL-3 construct where the arginines in all the six RGG repeats have been mutated to glycine or leucine (RGG_mut). Therefore, P granule assembly is promoted by the presence of mRNA, and mRNA requires RGG repeats in PGL-3 in order to promote drop formation. Consistent with this result, mRNA concentrated within PGL-3 drops."
21,PMID: 27594427,RNAPS0000171,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,18S,1754nt(1-1754),AUACCUGAUUGAUUCUGUCAGCGCGAUAUGCUCAAGUAAAAGAUUAAGCCAUGCAUGCUUUGAUUCAUCAAUGAAAUUGCGUACGGCUCAUUAGAGCAGAUAUCACCUUAUCCGGGAUCCUCAUAUGGAUAACUGCGGAAAUACUGGAGCUAAUACAUGCAACUAUACCCCAACGCAAGGCGGGGUGCAAUUAUUAGAACAGACCAAACGUUUUCGGACGUUGUUUGUUGACUCUGAAUAAAGCAGUUUACUGUCAGUUUCGACUGACUCUAUCCGGAAAGGGUGUCUGCCCUUUCAACUAGAUGGUAGUUUAUUGGACUACCAUGGUUGUUACGGGUAACGGAGAAUAAGGGUUCGACUCCGGAGAGGGAGCCUUAGAAACGGCUACCACGUCCAAGGAAGGCAGCAGGCGCGAAACUUAUCCACUGUUGAGUAUGAGAUAGUGACUAAAAAUAUAAAGACUCAUCCUUUUGGAUGAGUUAUUUCAAUGAGUUGAAUACAAAUGAUUCUUCGAGUAGCAAGGAGAGGGCAAGUCUGGUGCCAGCAGCCGCGGUAAUUCCAGCUCUCCUAGUGUAUCUCGUUAUUGCUGCGGUUAAAAAGCUCGUAGUUGGAUCUAGGUUACGUGCCGCAGUUCGCAAUUUGCGUCAACUGUGGUCGUGACUUCUAAUUUGCUGGUUUGAGGUUGGGUUCGCCCUUCAACUGCCAGCAGGUUUACCUUGAAUAAAUCAGAGUGCUCAAUACAAGCGCUUGCUUGAAUAGCUCAUCAUGGAAUAAUGAAACAGGACUUCGGUUCUUUUUGUUGGUUCUAGAACUGAUUUAAUGGUUAAGAGGGACAAACCGGGGGCAUUCGUAUCAUUACGCGAGAGGUGAAAUUCGUGGACCGUAGUGAGACGCCCAACAGCGAAAGCAUUUGCCAAGAAUGUCUUCAUUAAUCAAGAACGAAAGUCAGAGGUUCGAAGGCGAUUAGAUACCGCCCUAGUUCUGACCGUAAACGAUGCCAUCUCGCGAUUCGGAGGGUUUUUGCCCUGCCGAGGAGCUAUCCGGAAACGAAAGUCUUUCGGUUCCGGGGGUAGUAUGGUUGCAAAGCUGAAACUUAAAGAAAUUGACGGAAGGGCACCACAAGGCGUGGAGCUUGCGGCUUAAUUUGACUCAACACGGGAAAACUCACCCGGUCCGGACACCAUUAGGACUGACAGAUUGAAAGCUCUUUCUCGAUUUGGUGGUUGGUGGUGCAUGGCCGUUCUUAGUUGGUGGAGUGAUUUGUCUGGUUUAUUCCGAUAACGAGCGAGACUCUAGCCUGCUAAAUAGUUGGCGAAUCUUCGGGUUCGUAUAACUUCUUAGAGGGAUAAGCGGUGUUUAGCCGCACGAGAUUGAGCGAUAACAGGUCUGUGAUGCCCUUAGAUGUCCGGGGCUGCACGCGUGCUACACUGGUGGAGUCAGCGGGUUUUUCCUAUGCCGAAAGGUAUCGGUAAACCGUUGAAAUUCUUCCAUGUCCGGGAUAGGGUAUUGUAAUUAUUGCCCUUAAACGAGGAAUGCCUAGUAAGUGUGAGUCAUCAGCUCACGUUGAUUACGUCCCUGCCCUUUGUACACACCGCCCGUCGCUAUCCGGGACUGAACUGAUUCGAGAAGAGUGGGGACUGUCGCUUCGAGGUUUAACGACUUCGUUGUUGCGGAAACCAUUUUUAUCGCAUUGGUUUGAACCGGGUAAAAGUCGUAACAAGGUAGCUGUAGGUGAACCUGCAGCUGGAUCAUCG,rRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,10-100 ng/µl rRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,solute,"In-vitro-transcribed 18S rRNA did not promote assembly of PGL-3 drops over a broad range of concentrations (10–100 ng/ml). Heating the rRNA made it assembly competent, which suggests that the complex structures of rRNA attenuate its ability to promote PGL-3 drops."
22,PMID: 27594427,RNAPS0000171,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,18S,1754nt(1-1754),AUACCUGAUUGAUUCUGUCAGCGCGAUAUGCUCAAGUAAAAGAUUAAGCCAUGCAUGCUUUGAUUCAUCAAUGAAAUUGCGUACGGCUCAUUAGAGCAGAUAUCACCUUAUCCGGGAUCCUCAUAUGGAUAACUGCGGAAAUACUGGAGCUAAUACAUGCAACUAUACCCCAACGCAAGGCGGGGUGCAAUUAUUAGAACAGACCAAACGUUUUCGGACGUUGUUUGUUGACUCUGAAUAAAGCAGUUUACUGUCAGUUUCGACUGACUCUAUCCGGAAAGGGUGUCUGCCCUUUCAACUAGAUGGUAGUUUAUUGGACUACCAUGGUUGUUACGGGUAACGGAGAAUAAGGGUUCGACUCCGGAGAGGGAGCCUUAGAAACGGCUACCACGUCCAAGGAAGGCAGCAGGCGCGAAACUUAUCCACUGUUGAGUAUGAGAUAGUGACUAAAAAUAUAAAGACUCAUCCUUUUGGAUGAGUUAUUUCAAUGAGUUGAAUACAAAUGAUUCUUCGAGUAGCAAGGAGAGGGCAAGUCUGGUGCCAGCAGCCGCGGUAAUUCCAGCUCUCCUAGUGUAUCUCGUUAUUGCUGCGGUUAAAAAGCUCGUAGUUGGAUCUAGGUUACGUGCCGCAGUUCGCAAUUUGCGUCAACUGUGGUCGUGACUUCUAAUUUGCUGGUUUGAGGUUGGGUUCGCCCUUCAACUGCCAGCAGGUUUACCUUGAAUAAAUCAGAGUGCUCAAUACAAGCGCUUGCUUGAAUAGCUCAUCAUGGAAUAAUGAAACAGGACUUCGGUUCUUUUUGUUGGUUCUAGAACUGAUUUAAUGGUUAAGAGGGACAAACCGGGGGCAUUCGUAUCAUUACGCGAGAGGUGAAAUUCGUGGACCGUAGUGAGACGCCCAACAGCGAAAGCAUUUGCCAAGAAUGUCUUCAUUAAUCAAGAACGAAAGUCAGAGGUUCGAAGGCGAUUAGAUACCGCCCUAGUUCUGACCGUAAACGAUGCCAUCUCGCGAUUCGGAGGGUUUUUGCCCUGCCGAGGAGCUAUCCGGAAACGAAAGUCUUUCGGUUCCGGGGGUAGUAUGGUUGCAAAGCUGAAACUUAAAGAAAUUGACGGAAGGGCACCACAAGGCGUGGAGCUUGCGGCUUAAUUUGACUCAACACGGGAAAACUCACCCGGUCCGGACACCAUUAGGACUGACAGAUUGAAAGCUCUUUCUCGAUUUGGUGGUUGGUGGUGCAUGGCCGUUCUUAGUUGGUGGAGUGAUUUGUCUGGUUUAUUCCGAUAACGAGCGAGACUCUAGCCUGCUAAAUAGUUGGCGAAUCUUCGGGUUCGUAUAACUUCUUAGAGGGAUAAGCGGUGUUUAGCCGCACGAGAUUGAGCGAUAACAGGUCUGUGAUGCCCUUAGAUGUCCGGGGCUGCACGCGUGCUACACUGGUGGAGUCAGCGGGUUUUUCCUAUGCCGAAAGGUAUCGGUAAACCGUUGAAAUUCUUCCAUGUCCGGGAUAGGGUAUUGUAAUUAUUGCCCUUAAACGAGGAAUGCCUAGUAAGUGUGAGUCAUCAGCUCACGUUGAUUACGUCCCUGCCCUUUGUACACACCGCCCGUCGCUAUCCGGGACUGAACUGAUUCGAGAAGAGUGGGGACUGUCGCUUCGAGGUUUAACGACUUCGUUGUUGCGGAAACCAUUUUUAUCGCAUUGGUUUGAACCGGGUAAAAGUCGUAACAAGGUAGCUGUAGGUGAACCUGCAGCUGGAUCAUCG,rRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,＞100 ng/µl rRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"In-vitro-transcribed 18S rRNA did not promote assembly of PGL-3 drops over a broad range of concentrations (10–100 ng/ml). Heating the rRNA made it assembly competent, which suggests that the complex structures of rRNA attenuate its ability to promote PGL-3 drops."
23,PMID: 27594427,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,[pgl-3]:693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,200 ng/µl RNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,we looked at the role of RNA in triggering PGL-3 phase separation in vitro. We found that total RNA purified from C. elegans (200 ng/ml) promoted PGL-3 drop assembly
24,PMID: 27594427,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,[pgl-3]:693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,10 ng/µl RNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"Consistent with the estimated in vivo concentration of mRNA in C. elegans embryos, we found that physiological concentration of mRNA (100 nM, or 50 ng/ml assuming average length of mRNA is 1.5 kb) can promote assembly of drops at physiological concentrations of PGL-3"
25,PMID: 28683104,RNAPS0000402,https://pubmed.ncbi.nlm.nih.gov/28683104,RNAs + protein,-,-,yeast tRNA,-(25 kDa),-,tRNA,yeast,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|[Tau C]:tRNA were maintained at a mass ratio of 7:1 (corresponding to a charge ratio of 1.2:1) and a total mass concentration of 2 mg/ml,0-50 NaCl,20 mM ammonium acetate at pH 7,RT,> 10 min,-,Bright-field microscopy,liquid,"The systematic increase in salt concentration decreased the amount of tau-RNA droplet, the droplets reproducibly disappeared when the salt concentration was increased to 100 mM or higher"
26,PMID: 28683104,RNAPS0000402,https://pubmed.ncbi.nlm.nih.gov/28683104,RNAs + protein,-,-,yeast tRNA,-(25 kDa),-,tRNA,yeast,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|[Tau C]:tRNA were maintained at a mass ratio of 7:1 (corresponding to a charge ratio of 1.2:1) and a total mass concentration of 2 mg/ml,≥100 mM NaCl,20 mM ammonium acetate at pH 7,RT,> 10 min,-,Bright-field microscopy,solute,"The systematic increase in salt concentration decreased the amount of tau-RNA droplet, the droplets reproducibly disappeared when the salt concentration was increased to 100 mM or higher"
27,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T26,30,68,84,87,117E
MASNDYTQQATQSYGAYPTQPGQGYEQQSEQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T26,30,68,84,87,117E
MASNDYTQQATQSYGAYPTQPGQGYEQQSEQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|0.05-0.5 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,liquid,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
28,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T7,11,19,68,26,30,42,61,84,87,117,131E
MASNDYEQQAEQSYGAYPEQPGQGYEQQSEQPYGQQSYSGYEQSTDTSGYGQSSYSSYGQ
EQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYEQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T7,11,19,68,26,30,42,61,84,87,117,131E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[2-10],[26-28],[40-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|≤0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,liquid,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
29,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T7,11,19,68,26,30,42,61,84,87,117,131E
MASNDYEQQAEQSYGAYPEQPGQGYEQQSEQPYGQQSYSGYEQSTDTSGYGQSSYSSYGQ
EQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYEQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T7,11,19,68,26,30,42,61,84,87,117,131E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[2-10],[26-28],[40-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|≥0.27 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,solute,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
30,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0-0.5 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,liquid,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
31,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T26,30,68,84,87,117E
MASNDYTQQATQSYGAYPTQPGQGYEQQSEQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T26,30,68,84,87,117E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,≤ 1 d,other_molecular:agitation 1200 rpm,Differential interference contrast microscopy,liquid,"Non-agitated FUS WT, 6E, and 12E formed similar liquid-like droplets, as observed by DIC microscopy up to 1 day. However, agitation 1,200 rpm, 25°C, 1 day induces wild-type to form irregular aggregate, while assemblies of 6E and 12E remained spherical, with or without RNA (0.4:1 FUS, by mass)."
32,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T7,11,19,68,26,30,42,61,84,87,117,131E
MASNDYEQQAEQSYGAYPEQPGQGYEQQSEQPYGQQSYSGYEQSTDTSGYGQSSYSSYGQ
EQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYEQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T7,11,19,68,26,30,42,61,84,87,117,131E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[2-10],[26-28],[40-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,≤ 1 d,other_molecular:agitation 1200 rpm,Differential interference contrast microscopy,liquid,"Non-agitated FUS WT, 6E, and 12E formed similar liquid-like droplets, as observed by DIC microscopy up to 1 day. However, agitation 1,200 rpm, 25°C, 1 day induces wild-type to form irregular aggregate, while assemblies of 6E and 12E remained spherical, with or without RNA (0.4:1 FUS, by mass)."
33,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,≤ 1 d,other_molecular:agitation 1200 rpm,Differential interference contrast microscopy,"liquid, solid","Non-agitated FUS WT, 6E, and 12E formed similar liquid-like droplets, as observed by DIC microscopy up to 1 day. However, agitation 1,200 rpm, 25°C, 1 day induces wild-type to form irregular aggregate, while assemblies of 6E and 12E remained spherical, with or without RNA (0.4:1 FUS, by mass)."
34,PMID: 28877466,RNAPS0000121,https://pubmed.ncbi.nlm.nih.gov/28877466,RNAs + protein,-,-,Sf9 RNA,-,-,total RNA,Sf9 cell line(Spodoptera frugiperda),"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=441aa|residues=1-441
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,25 µM [Tau];|150 ng/µl RNA,150 mM KCl,"25 mM HEPES, pH 7.4",RT,-,crowding agent:0-4% dextran,Total internal reflection fluorescence microscopy,solute,"Because drop formation seems to be driven by electrostatic interaction and tau-tubulin interaction is also mediated by charge, we wondered whether RNA could also enhance the formation of tau drops (Saha et al., 2016)."
35,PMID: 28877466,RNAPS0000121,https://pubmed.ncbi.nlm.nih.gov/28877466,RNAs + protein,-,-,Sf9 RNA,-,-,total RNA,Sf9 cell line(Spodoptera frugiperda),"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=441aa|residues=1-441
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,25 µM [Tau];|150 ng/µl RNA,150 mM KCl,"25 mM HEPES, pH 7.4",RT,-,crowding agent:6-10% dextran,Total internal reflection fluorescence microscopy,liquid,"Because drop formation seems to be driven by electrostatic interaction and tau-tubulin interaction is also mediated by charge, we wondered whether RNA could also enhance the formation of tau drops (Saha et al., 2016)."
36,PMID: 29210575,RNAPS0000410,https://pubmed.ncbi.nlm.nih.gov/29210575,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1|length=238aa|residues=1-238|mutation=E34K,T105K,E142R,N149K
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGKGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKKRAEVKFEGDTLV
NRIELKGIDFKEDGNILGHKLRYNYNSHKVYIMADKQKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,"protein_mutation:E34K,T105K,E142R,N149K",238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/","[1-7],[114-121],[179-219]",-,In vitro,[GFP] and RNA solutions were mixed together at protein mass fractions centered on 0.68 with 0.2 mg mL-1 total concentration.,-,10 mM Tris (pH 7.4),25˚C,-,-,Phase contrast microscopy,liquid,"Since GFP/RNA pairs phase separated as liquid-liquid rather than solid-liquid like most of the other GFP/polyanion pairs, we hypothesized GFP/synthetic polyanion pairs may also phase separate as liquid-liquid at other protein mass fractions. GFP/polyanion were mixed at varying ratios in 10 mM Tris (pH 7.4) at 0.2 mg mL-1 total macromolecular concentration, incubated at 25 ⁰C, then imaged by phase contrast microscopy. Each of the GFP/synthetic polyanion pairs formed liquid-liquid and not solid-liquid phase separations at protein mass fractions lower than the midpoint of turbidity, while at protein mass fractions greater than the midpoint of turbidity both GFP/PAA and GFP/PSS formed solid-liquid phase separations. Interestingly, DNA/GFP pairs formed only solid-liquid phase separations at each protein mass fraction, while RNA/GFP formed only liquid-liquid phase separations."
37,PMID: 29210575,RNAPS0000410,https://pubmed.ncbi.nlm.nih.gov/29210575,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1|length=238aa|residues=1-238|mutation=D19K,E32K,D133K
MSKGEELFTGVVPILVELKGDVNGHKFSVSGKGEGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIELKGIDFKEKGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,"protein_mutation:D19K,E32K,D133K",238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/","[1-7],[115-118],[179-219]",-,In vitro,[GFP] and RNA solutions were mixed together at protein mass fractions centered on 0.64 with 0.2 mg mL-1 total concentration.,-,10 mM Tris (pH 7.4),25˚C,-,-,Phase contrast microscopy,liquid,"Since GFP/RNA pairs phase separated as liquid-liquid rather than solid-liquid like most of the other GFP/polyanion pairs, we hypothesized GFP/synthetic polyanion pairs may also phase separate as liquid-liquid at other protein mass fractions. GFP/polyanion were mixed at varying ratios in 10 mM Tris (pH 7.4) at 0.2 mg mL-1 total macromolecular concentration, incubated at 25 ⁰C, then imaged by phase contrast microscopy. Each of the GFP/synthetic polyanion pairs formed liquid-liquid and not solid-liquid phase separations at protein mass fractions lower than the midpoint of turbidity, while at protein mass fractions greater than the midpoint of turbidity both GFP/PAA and GFP/PSS formed solid-liquid phase separations. Interestingly, DNA/GFP pairs formed only solid-liquid phase separations at each protein mass fraction, while RNA/GFP formed only liquid-liquid phase separations."
38,PMID: 29210575,RNAPS0000410,https://pubmed.ncbi.nlm.nih.gov/29210575,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1|length=238aa|residues=1-238|mutation=V11K,E124K,Q157R,D190R
MSKGEELFTGKVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIKLKGIDFKEDGNILGHKLEYNYNSHNVYIMADKRKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGRGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,"protein_mutation:V11K,E124K,Q157R,D190R",238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/","[1-10],[23-29],[114-118],[161-166],[179-219]",-,In vitro,[GFP] and RNA solutions were mixed together at protein mass fractions 0.60 with 1 mg mL-1 total concentration.,400-500 mM NaCl,10 mM Tris (pH 7.4),25˚C,-,-,Phase contrast microscopy,liquid,"Effect of NaCl on GFP(+26)/RNA phase separation morphology. NaCl was titrated into GFP(+26)/RNA after intial mixing in 10 mM Tris (pH 7.4) with 0 mM NaCl. Similar to GFP/PAA pairs, the GFP(+26)/RNA dense phase transitioned from solid to liquid at NaCl concentrations corresponding to the plateau in salt titration experiments."
39,PMID: 29472250,RNAPS0000477,https://pubmed.ncbi.nlm.nih.gov/29472250,RNAs + protein,-,-,Homo sapiens brain RNA,-,-,total RNA,Homo sapiens,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=441aa|residues=1-441
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,protein_ptm:Phosphorylation,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,2 µM [Tau];|0.5 mg/ml RNA,50 mM NaCl,10 mM HEPES pH 7.4,RT,> 0 min,-,"Electron microscopy,FRAP,Atomic force microscopy",liquid,"The addition of heparin or RNA to phosphorylated p-tau441 led to spontaneous formation of p-tau441 droplets, even in the absence of PEG. While, Non-phosphorylated tau441 did not show LLPS with heparin and RNA at the same low protein concentration (2 uM) and in the same buffer conditions."
40,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|llength=297aa|residues=1-294|mutation=A3 to GGS repeats
GSHMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDEL
HIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLV
AVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAAGGSGGSGGSGGSGGSGG
SGGSGGSGGSGKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKT
PKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,protein_mutation:IDR [A3 tract] to GGS repeats,297aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/","[1-14],[44-62],[80-81],[117-233],[294-294],[297-297]",-,In vitro,≥1 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,liquid,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
41,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|llength=296aa|residues=1-294|mutation=B1 R/K to A
GSHMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDEEHQLSLRTVSLGAGAKDELH
IVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVA
VEEDAESEDEEEEDVALLSISGARSAPGGGSAVPQAAVALAADEDDDDDDEEDDDEDDDD
DDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTP
KGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,protein_mutation: [moderately charged basic tracts B1] R/K to A,296aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/","[1-14],[44-61],[79-80],[116-232],[293-293],[296-296]",-,In vitro,≥10 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,liquid,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
42,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|llength=297aa|residues=1-294|mutation=B2 R/K to A
GSHMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDEL
HIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLV
AVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDD
DDDFDDEEAEEAAPVAASIRDTPAANAQASNQNGADSAPSSTPRSAGQESFAAQEATPAT
PAGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,protein_mutation: [moderately charged basic tracts B2] R/K to A,297aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/","[1-14],[44-62],[80-81],[117-251],[294-294],[297-297]",-,In vitro,0.1-100 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,solute,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
43,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=296aa|residues=1-294
GSMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELH
IVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVA
VEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDD
DDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTP
KGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,-,296aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,≥10 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,liquid,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
44,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=G156E
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYEQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:D19K,E32K,D133K",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|100 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,> 24 h,-,Confocal Laser scanning microscopy,liquid,"Thus,we next tested whether the addition of RNA prevents the formation of fibrils in vitro. The addition of RNA kept the droplets in a soluble state, and fibers were not seen (Fig. 4A). We next investigated whether RNA also changes the material properties of FUS assemblies in vivo."
45,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0-800 ng/µl rRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
46,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0-400 ng/µl tRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
47,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,0-3 µM [FUS];|50 ng/µl RNA ,"50-300 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"We estimated that the nuclear RNA concentration is ~10.6 times as high as that required for droplet dissolution in vitro (fig. S7 and supplementary methods). However, ~1% of nuclear FUS formed condensates (paraspeckles) (Fig. 1E) by binding to the noncoding RNA Neat1. To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA. This led to a reappearance of FUS droplets"
48,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|100-200 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
49,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|300 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,solute,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
50,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|300 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,other_molecular:5 ng/µl RNase A,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
51,PMID: 29650702,RNAPS0000155,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,12.5 µM [HNRNPA1];|100-800 ng/µl RNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
52,PMID: 29650702,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,10 µM [TDP-43];|100-800 ng/µl RNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
53,PMID: 29650702,RNAPS0000027,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-;|NCBI ID:283131,-;|https://www.ncbi.nlm.nih.gov/gene/283131,Hela RNA;|NEAT1,-;|-,-;|-,total RNA;|lncRNA,Hela cell line(Homo sapiens);|Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl rRNA;|100 ng/µl Neat1,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA or rRNA. This led to a reappearance of FUS droplets. We attribute this result to the ability of Neat1 to form large RNA assemblies, which subsequently recruit FUS. This observation suggests that highly structured RNAs such as Neat1 act as scaffolds that promote the nucleation of condensates in the high-RNA concentration environment of the nucleus. A similar scenario may apply for stress granules in the cytoplasm, which contain large amounts of structured polyadenylated mRNA."
54,PMID: 29650702,RNAPS0000027,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-;|NCBI ID:283131,-;|https://www.ncbi.nlm.nih.gov/gene/283131,Hela RNA;|NEAT1,-;|-,-;|-,total RNA;|lncRNA,Hela cell line(Homo sapiens);|Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl tRNA;|100 ng/µl Neat1 ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA or rRNA. This led to a reappearance of FUS droplets. We attribute this result to the ability of Neat1 to form large RNA assemblies, which subsequently recruit FUS. This observation suggests that highly structured RNAs such as Neat1 act as scaffolds that promote the nucleation of condensates in the high-RNA concentration environment of the nucleus. A similar scenario may apply for stress granules in the cytoplasm, which contain large amounts of structured polyadenylated mRNA."
55,PMID: 29650702,RNAPS0000027,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-;|NCBI ID:283131,-;|https://www.ncbi.nlm.nih.gov/gene/283131,Hela RNA;|NEAT1,-;|-,-;|-,total RNA;|lncRNA,Hela cell line(Homo sapiens);|Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl Neat1;|100 ng/µl tRNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,solute,"To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA or rRNA. This led to a reappearance of FUS droplets. We attribute this result to the ability of Neat1 to form large RNA assemblies, which subsequently recruit FUS. This observation suggests that highly structured RNAs such as Neat1 act as scaffolds that promote the nucleation of condensates in the high-RNA concentration environment of the nucleus. A similar scenario may apply for stress granules in the cytoplasm, which contain large amounts of structured polyadenylated mRNA."
56,PMID: 29650703,RNAPS0000055,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:850639,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/850639,BNI1;|SPA2,5862nt(1-5862);|4401nt(1-4401),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|AUGGGUACGUCAAGCGAGGUUUCUCUCGCACAUCAUAGAGAUAUCUUCCAUUACUACGUCUCACUGAAGACUUUUUUCGAGGUGACUGGCGAAAAUCGUGACAGGUCAAAUUCGACACGAGCUCAAAAGGCCAGAGCCAAGCUGUUGAAGCUAUCUUCUUCGCAAUUUUACGAGCUGAGUACAGACGUGUCCGAUGAGCUGCAGAGGAGAAUCGGUGAAGAUGCUAACCAACCAGAUUACCUUUUGCCGAAGGCAAAUUUCCACAUGAAAAGGAACCAGGCUAGACAGAAACUGGCCAAUCUAUCACAAACUCGAUUUAAUGAUUUGUUGGACGAUAUCCUUUUUGAGAUCAAGAGAAGAGGGUUCGACAAGGAUUUGGAUGCUCCACGGCCCCCAUUACCGCAGCCGAUGAAACAAGAGGUCAGCAAAGACAGCGAUGAUACUGCAAGAACAUCCACAAAUUCUUCCUCUGUGACUCAAGUAGCUCCAAACGUCUCCGUACAACCUUCUUUGGUCAUUCCUAAGAUGGCAUCUAUCGAUUGGUCUUCUGAGGAAGAAGAAGAGGAGCAAGUAAAGGAGAAGCCAAAUGAACCGGAGGGAAAACAAACAAGCAUGGAUGAAAAGAAAGAGGCUAAACCUGCUCUAAACCCCAUAGUUACAGAUUCUGAUCUGCCUGACUCCCAAGUGCUCGCUCGUGAUAUCACAUCAAUGGCAAGGACUCCAACAACGACGCAUAAAAAUUACUGGGACGUUAAUGAUUCUCCAAUUAUCAAGGUAGAUAAAGAUAUCGAUAACGAAAAGGGUCCCGAACAGUUGAAGAGCCCUGAAGUACAACGGGCUGAGAACAAUAACCCUAACUCAGAGAUGGAAGACAAGGUUAAAGAACUGACUGAUUUAAACAGCGACUUACAUUUGCAAAUUGAAGAUUUGAAUGCUAAGUUAGCAUCUUUAACCAGCGAGAAGGAAAAGGAGAAGAAGGAAGAGAAGGAGGAAAAAGAAAAGGAAAAGAACUUAAAGAUUAACUACACCAUUGAUGAAAGUUUUCAGAAAGAAUUGCUGUCAUUAAACUCUCAAAUCGGUGAAUUAUCAAUUGAGAAUGAAAAUUUGAAGCAGAAAAUUUCAGAAUUCGAACUGCAUCAAAAAAAGAAUGACAACCAUAAUGAUUUGAAAAUCACUGACGGUUUUAUUAGCAAGUACUCUUCUGCCGAUGGGCUCAUUCCAGCUCAAUACAUCUUAAACGCUAACAACUUGAUAAUUCAAUUUACUACUAGGCUUUCCGCAGUACCCAUAGGCGACUCCACGGCAAUUUCCCAUCAAAUUGGCGAAGAGUUAUUUCAAAUAUUAUCCCAGUUAUCGAACCUAAUCUCCCAGCUAUUACUAUCGGCCGACCUAUUACAGUACAAAGAUCAGGUCAUUUUACUGAAGGCAUCAUUAUCGCAUGCGAUCACAUCGAUAAGAUAUUUCUCUGUUUACGGUCCCGUAUUAAUUCCGAAAAUAACUGUGCAAGCUGCUGUUUCAGAGGUUUGUUUUGCCAUGUGUAAUCUAAUUGAUUCAGCGAAAAUAAAAUCCGAUUCAAAUGGUGAGAGCACCACCUCUAAUGAAGGUAACCGACAGGUAUUAGAAUAUUCUUCACCAACUGCUACCACCCCAAUGACGCCAACUUUCCCCUCGACUUCUGGAAUAAAUAUGAAGAAGGGGUUUAUAAACCCAAGAAAACCAGCAUCUUUCUUGAAUGAUGUGGAGGAAGAAGAAUCUCCAGUCAAGCCAUUGAAAAUUACACAAAAGGCAAUUAACAGUCCGAUCAUAAGACCGUCAUCGUCUAAUGGAGUUCCAACAACCUCAAGAAAACCUUCAGGAACGGGGCUAUUUAGUUUAAUGAUUGAUUCAUCAAUUGCUAAGAAUAGCUCCCAUAAAGAGGAUAAUGAUAAAUAUGUCUCGCCCAUAAAGGCAGUAACAUCGGCCUCCAAUUCUGCAAGUAGCAAUAUUUCCGAAAUUCCUAAACUAACACUACCUCCACAAGCCAAAAUCGGUACUGUUAUUCCACCGUCAGAGAAUCAAGUUCCCAAUAUUAAAAUCGAGAAUACAGAAGAGGAUAAUAAAAGGAGUGACAUAACAAAUGAAAUCUCUGUUAAACCAACUUCUAGCAUUGCUGAUAAACUGAAACAAUUUGAGCAAAGUUCCGAAAAGAAAUCAUCACCAAAGGAAAAUCCUAUAGCAAAAGAAGAAAUGGAUUCAAAACCAAAACUAUCCAAUAAAUUUAUCACUUCAAUGAAUGAUGUGUCCACAGAUGAUUCAAGCUCUGAUGGUAACGAAAAUGACGAUGCAGACGAUGAUGAUGAUUUUACCUAUAUGGCAUUGAAACAAACAAUGAAGAGAGAAGGUUCAAAAAUUGAAAAAAAUAAUGACAGCAAACUACCUGCAAAUAUAGUGGAACUUGAUUUACAUGAGUCACCGGAGUCCGUGAAGAUUGAAUCUCCUGAAUCGAUAAAGGAAAUCACGUCAUCUGAAAUGUCUUCAGAAAUGCCAAGUAGUUCGCUGCCUAAGAGAUUAGUAGAGGAUGUUGAGCCUUCAGAAAUGCCAGAGAAGGGCGCAUCUGUAGAAUCAGUCAGGAAGAAAAAUUUUCAAGAACCACUUGGUAAUGUCGAAUCUCCGGAUAUGACGCAGAAGGUCAAGUCUUUGGGUAUGACAGGAAAGGCUGUAGGCCCAGAAUCAGAUAGUAGGGUCGAAUCUCCGGGCAUGACAGGACAGAUUAAAUCUUUGAAUAUGGCAGGAAAAGUUGUAGGCCCAGAAGCAGAUAGUAGGGUCGAAUCUCCGGGCAUGAAAGAGCAGAUUAAGUCUUUGGGUAUGACAGGAAAAAUUACAGCUCAAGAAUCAAUCAAGUCCCCGGAAGCGGCUAGGAAGUUGGCGUCAUCAGGAGAAGUUGACAAAAUUGAAUCUCCAAGAAUGGUAAGGGAAAGCGAGUCCUUGGAGGCAGUAGGCAAUACUAUCCCCUCAAACAUGACAGUGAAAAUGGAAUCCCCAAAUUUAAAGGGAAAUACUGUGUCUGAACCUCAAGAAAUAAGGAGAGACAUUGCCUCCUCAGAGCCGAUAGAGAAUGUUGACCCCCCAAAAGUACUAAAAAAGAUUGUCUUUCCAAAGGCUGUUAAUAGAACUGGAUCACCAAAAUCAGUCGAAAAGACUCCAUCUUCAGCUACACUGAAAAAGAGCGGGCUCCCAGAACCGAAUAGCCAAAUUGUUUCUCCUGAAUUGGCAAAAAAUUCACCUCUAGCACCGAUAAAGAAAAAUGUCGAGUUACGAGAAACUAAUAAACCACAUACUGAGACUAUCACUUCUGUGGAACCAACAAACAAGGAUGCCAAUACUUCUUGGAGAGACGCCGACUUAAACCGUACGAUCAAACGAGAGGAGGAGGACGAAGAUUUUGAUAGAGUGAACCACAAUAUCCAGAUCACUGGUGCAUAUACGAAAACUGGAAAAAUUGAUUAUCAUAAAAUACCUGUUGAUCGUAAAGCAAAAAGCGAAGCAGAAGUGCAUACUUCCGAGGAAGAUAUUGAUGAAUCAAAUAAUGUUAAUGGAAAAAGAGCUGAUGCCCAAAUACACAUCACUGAAAGAAAGCAUGCUUUCGUAAAUCCAACUGAAAAUUCACAGGUAAAAAAGACGAGCCACUCACCAUUUUUAAACAGUAAACCGGUUCAAUACGAGAACUCAGAGUCGAACGGCGGCAUUAACAACCACAUAAAGAUAAAAAAUACUGGAGAAACUACGGCACAUGACGAGAAACAUUAUAGUGAUGAUGAUGAUUCUAGCUAUCAAUUUGUUCCCAUGAAACAUGAAGAACAAGAACAAGAACAAAACAGAAGUGAGGAAGAGGAAAGUGAAGAUGACGAUGAAGAGGAAGAAGACAGUGAUUUUGAUGUGGAUACAUUUGACAUUGAAAAUCCGGAUAAUACACUAUCAGAGUUACUAUUGUAUUUAGAACAUCAAACAAUGGACGUCAUAUCCACGAUUCAAUCGCUUUUGACAUCGAUCAAGAAACCACAGGUGACGAAGGGUAAUUUGAGGGGAGAAUCGAAUGCAAUCAACCAAGUCAUAGGUCAAAUGGUGGACGCUACUAGCAUAUCAAUGGAGCAAAGCAGAAAUGCCAAUUUGAAGAAACACGGUGAUUGGGUGGUGCAAAGUCUAAGAGACUGUUCGCGUAGAAUGACAAUUUUGUGCCAAUUAACUGGCGAUGGAAUACUAGCGAAGGAAAAGAGCGAUCAAGAUUAUGCUGACAAAAACUUCAAACAGCGGUUGGCAGGGAUUGCGUUUGAUGUUGCCAAAUGUACAAAGGAGCUGGUAAAAACUGUAGAAGAGGCAAGUUUGAAGGACGAAAUAAAUUAUUUGAAUUCGAAGUUGAAGUAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,2 µM [Whi3];|1.25 nM BNI1;|1.25 nM SPA2,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and quantification show SPA2 mRNA incubated with oligos to target the complement nucleotide regions of BNI1 (5 nM) is less recruited into preformed Whi3-BNI1 droplets (8 µM Whi3, 5 nM BNI1) compared to native SPA2 alone."
57,PMID: 29650703,RNAPS0000055,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:850639,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/850639,BNI1;|SPA2,5862nt(1-5862);|4401nt(1-4401),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|AUGGGUACGUCAAGCGAGGUUUCUCUCGCACAUCAUAGAGAUAUCUUCCAUUACUACGUCUCACUGAAGACUUUUUUCGAGGUGACUGGCGAAAAUCGUGACAGGUCAAAUUCGACACGAGCUCAAAAGGCCAGAGCCAAGCUGUUGAAGCUAUCUUCUUCGCAAUUUUACGAGCUGAGUACAGACGUGUCCGAUGAGCUGCAGAGGAGAAUCGGUGAAGAUGCUAACCAACCAGAUUACCUUUUGCCGAAGGCAAAUUUCCACAUGAAAAGGAACCAGGCUAGACAGAAACUGGCCAAUCUAUCACAAACUCGAUUUAAUGAUUUGUUGGACGAUAUCCUUUUUGAGAUCAAGAGAAGAGGGUUCGACAAGGAUUUGGAUGCUCCACGGCCCCCAUUACCGCAGCCGAUGAAACAAGAGGUCAGCAAAGACAGCGAUGAUACUGCAAGAACAUCCACAAAUUCUUCCUCUGUGACUCAAGUAGCUCCAAACGUCUCCGUACAACCUUCUUUGGUCAUUCCUAAGAUGGCAUCUAUCGAUUGGUCUUCUGAGGAAGAAGAAGAGGAGCAAGUAAAGGAGAAGCCAAAUGAACCGGAGGGAAAACAAACAAGCAUGGAUGAAAAGAAAGAGGCUAAACCUGCUCUAAACCCCAUAGUUACAGAUUCUGAUCUGCCUGACUCCCAAGUGCUCGCUCGUGAUAUCACAUCAAUGGCAAGGACUCCAACAACGACGCAUAAAAAUUACUGGGACGUUAAUGAUUCUCCAAUUAUCAAGGUAGAUAAAGAUAUCGAUAACGAAAAGGGUCCCGAACAGUUGAAGAGCCCUGAAGUACAACGGGCUGAGAACAAUAACCCUAACUCAGAGAUGGAAGACAAGGUUAAAGAACUGACUGAUUUAAACAGCGACUUACAUUUGCAAAUUGAAGAUUUGAAUGCUAAGUUAGCAUCUUUAACCAGCGAGAAGGAAAAGGAGAAGAAGGAAGAGAAGGAGGAAAAAGAAAAGGAAAAGAACUUAAAGAUUAACUACACCAUUGAUGAAAGUUUUCAGAAAGAAUUGCUGUCAUUAAACUCUCAAAUCGGUGAAUUAUCAAUUGAGAAUGAAAAUUUGAAGCAGAAAAUUUCAGAAUUCGAACUGCAUCAAAAAAAGAAUGACAACCAUAAUGAUUUGAAAAUCACUGACGGUUUUAUUAGCAAGUACUCUUCUGCCGAUGGGCUCAUUCCAGCUCAAUACAUCUUAAACGCUAACAACUUGAUAAUUCAAUUUACUACUAGGCUUUCCGCAGUACCCAUAGGCGACUCCACGGCAAUUUCCCAUCAAAUUGGCGAAGAGUUAUUUCAAAUAUUAUCCCAGUUAUCGAACCUAAUCUCCCAGCUAUUACUAUCGGCCGACCUAUUACAGUACAAAGAUCAGGUCAUUUUACUGAAGGCAUCAUUAUCGCAUGCGAUCACAUCGAUAAGAUAUUUCUCUGUUUACGGUCCCGUAUUAAUUCCGAAAAUAACUGUGCAAGCUGCUGUUUCAGAGGUUUGUUUUGCCAUGUGUAAUCUAAUUGAUUCAGCGAAAAUAAAAUCCGAUUCAAAUGGUGAGAGCACCACCUCUAAUGAAGGUAACCGACAGGUAUUAGAAUAUUCUUCACCAACUGCUACCACCCCAAUGACGCCAACUUUCCCCUCGACUUCUGGAAUAAAUAUGAAGAAGGGGUUUAUAAACCCAAGAAAACCAGCAUCUUUCUUGAAUGAUGUGGAGGAAGAAGAAUCUCCAGUCAAGCCAUUGAAAAUUACACAAAAGGCAAUUAACAGUCCGAUCAUAAGACCGUCAUCGUCUAAUGGAGUUCCAACAACCUCAAGAAAACCUUCAGGAACGGGGCUAUUUAGUUUAAUGAUUGAUUCAUCAAUUGCUAAGAAUAGCUCCCAUAAAGAGGAUAAUGAUAAAUAUGUCUCGCCCAUAAAGGCAGUAACAUCGGCCUCCAAUUCUGCAAGUAGCAAUAUUUCCGAAAUUCCUAAACUAACACUACCUCCACAAGCCAAAAUCGGUACUGUUAUUCCACCGUCAGAGAAUCAAGUUCCCAAUAUUAAAAUCGAGAAUACAGAAGAGGAUAAUAAAAGGAGUGACAUAACAAAUGAAAUCUCUGUUAAACCAACUUCUAGCAUUGCUGAUAAACUGAAACAAUUUGAGCAAAGUUCCGAAAAGAAAUCAUCACCAAAGGAAAAUCCUAUAGCAAAAGAAGAAAUGGAUUCAAAACCAAAACUAUCCAAUAAAUUUAUCACUUCAAUGAAUGAUGUGUCCACAGAUGAUUCAAGCUCUGAUGGUAACGAAAAUGACGAUGCAGACGAUGAUGAUGAUUUUACCUAUAUGGCAUUGAAACAAACAAUGAAGAGAGAAGGUUCAAAAAUUGAAAAAAAUAAUGACAGCAAACUACCUGCAAAUAUAGUGGAACUUGAUUUACAUGAGUCACCGGAGUCCGUGAAGAUUGAAUCUCCUGAAUCGAUAAAGGAAAUCACGUCAUCUGAAAUGUCUUCAGAAAUGCCAAGUAGUUCGCUGCCUAAGAGAUUAGUAGAGGAUGUUGAGCCUUCAGAAAUGCCAGAGAAGGGCGCAUCUGUAGAAUCAGUCAGGAAGAAAAAUUUUCAAGAACCACUUGGUAAUGUCGAAUCUCCGGAUAUGACGCAGAAGGUCAAGUCUUUGGGUAUGACAGGAAAGGCUGUAGGCCCAGAAUCAGAUAGUAGGGUCGAAUCUCCGGGCAUGACAGGACAGAUUAAAUCUUUGAAUAUGGCAGGAAAAGUUGUAGGCCCAGAAGCAGAUAGUAGGGUCGAAUCUCCGGGCAUGAAAGAGCAGAUUAAGUCUUUGGGUAUGACAGGAAAAAUUACAGCUCAAGAAUCAAUCAAGUCCCCGGAAGCGGCUAGGAAGUUGGCGUCAUCAGGAGAAGUUGACAAAAUUGAAUCUCCAAGAAUGGUAAGGGAAAGCGAGUCCUUGGAGGCAGUAGGCAAUACUAUCCCCUCAAACAUGACAGUGAAAAUGGAAUCCCCAAAUUUAAAGGGAAAUACUGUGUCUGAACCUCAAGAAAUAAGGAGAGACAUUGCCUCCUCAGAGCCGAUAGAGAAUGUUGACCCCCCAAAAGUACUAAAAAAGAUUGUCUUUCCAAAGGCUGUUAAUAGAACUGGAUCACCAAAAUCAGUCGAAAAGACUCCAUCUUCAGCUACACUGAAAAAGAGCGGGCUCCCAGAACCGAAUAGCCAAAUUGUUUCUCCUGAAUUGGCAAAAAAUUCACCUCUAGCACCGAUAAAGAAAAAUGUCGAGUUACGAGAAACUAAUAAACCACAUACUGAGACUAUCACUUCUGUGGAACCAACAAACAAGGAUGCCAAUACUUCUUGGAGAGACGCCGACUUAAACCGUACGAUCAAACGAGAGGAGGAGGACGAAGAUUUUGAUAGAGUGAACCACAAUAUCCAGAUCACUGGUGCAUAUACGAAAACUGGAAAAAUUGAUUAUCAUAAAAUACCUGUUGAUCGUAAAGCAAAAAGCGAAGCAGAAGUGCAUACUUCCGAGGAAGAUAUUGAUGAAUCAAAUAAUGUUAAUGGAAAAAGAGCUGAUGCCCAAAUACACAUCACUGAAAGAAAGCAUGCUUUCGUAAAUCCAACUGAAAAUUCACAGGUAAAAAAGACGAGCCACUCACCAUUUUUAAACAGUAAACCGGUUCAAUACGAGAACUCAGAGUCGAACGGCGGCAUUAACAACCACAUAAAGAUAAAAAAUACUGGAGAAACUACGGCACAUGACGAGAAACAUUAUAGUGAUGAUGAUGAUUCUAGCUAUCAAUUUGUUCCCAUGAAACAUGAAGAACAAGAACAAGAACAAAACAGAAGUGAGGAAGAGGAAAGUGAAGAUGACGAUGAAGAGGAAGAAGACAGUGAUUUUGAUGUGGAUACAUUUGACAUUGAAAAUCCGGAUAAUACACUAUCAGAGUUACUAUUGUAUUUAGAACAUCAAACAAUGGACGUCAUAUCCACGAUUCAAUCGCUUUUGACAUCGAUCAAGAAACCACAGGUGACGAAGGGUAAUUUGAGGGGAGAAUCGAAUGCAAUCAACCAAGUCAUAGGUCAAAUGGUGGACGCUACUAGCAUAUCAAUGGAGCAAAGCAGAAAUGCCAAUUUGAAGAAACACGGUGAUUGGGUGGUGCAAAGUCUAAGAGACUGUUCGCGUAGAAUGACAAUUUUGUGCCAAUUAACUGGCGAUGGAAUACUAGCGAAGGAAAAGAGCGAUCAAGAUUAUGCUGACAAAAACUUCAAACAGCGGUUGGCAGGGAUUGCGUUUGAUGUUGCCAAAUGUACAAAGGAGCUGGUAAAAACUGUAGAAGAGGCAAGUUUGAAGGACGAAAUAAAUUAUUUGAAUUCGAAGUUGAAGUAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,20 µM [Whi3];|5 nM BNI1;|5 nM SPA2,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and quantification show SPA2 mRNA incubated with oligos to target the complement nucleotide regions of BNI1 (5 nM) is less recruited into preformed Whi3-BNI1 droplets (8 µM Whi3, 5 nM BNI1) compared to native SPA2 alone."
58,PMID: 29650703,RNAPS0000056,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_refold,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 refold,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Melted CLN3 mRNA that was slowly refolded (CLN3 refold) showed significantly less recruitment than melted, but more than native CLN3 (Fig. 3A and C). Mixing between melted CLN3 and melted BNI1 occurred in the presence of Whi3 and in RNA-only reactions, suggesting mixing is initiated by RNA-RNA interactions."
59,PMID: 29650703,RNAPS0000057,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_scr,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 scr,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"CLN3 mRNA heated to 95°C to disrupt secondary structure also readily incorporated into Whi3-BNI1 droplets (Fig. 3, A and C). Melted CLN3 mRNA that was slowly refolded (CLN3 refold) showed significantly less recruitment than melted, but more than native CLN3."
60,PMID: 29650703,RNAPS0000059,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_ml,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 ml,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,We next investigated which features of the mRNA sequence generate specificity. An mRNA with scrambled CLN3 coding sequence (cln3 scr) with intact Whi3-binding sites formed Whi3 droplets.
61,PMID: 29650703,RNAPS0000060,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_sm,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 sm,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Additionally, cln3sm, a mutant perturbing structure and exposing complementarity, co-localized with BNI1 transcripts in vitro and at polarity sites in cells (Fig. 3F, S5, >60% tips co-localized). Thus, secondary structure can regulate RNA sorting into distinct droplets through altering the capacity to form intermolecular interactions."
62,PMID: 29650703,RNAPS0000061,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,2 µM [Whi3];|1.25 nM BNI1;|1.25 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,Fluorescence microscopy images showing CLN3 is excluded from Whi3-BNI1 droplets in a variety of protein and RNA concentrations.
63,PMID: 29650703,RNAPS0000061,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,20 µM [Whi3];|5 nM BNI1;|5 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,Fluorescence microscopy images showing CLN3 is excluded from Whi3-BNI1 droplets in a variety of protein and RNA concentrations.
64,PMID: 29650703,RNAPS0000063,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:850639;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/850639;|https://www.ncbi.nlm.nih.gov/gene/1201,SPA2;|CLN3,4401nt(1-4401);|1879nt(1-1879),AUGGGUACGUCAAGCGAGGUUUCUCUCGCACAUCAUAGAGAUAUCUUCCAUUACUACGUCUCACUGAAGACUUUUUUCGAGGUGACUGGCGAAAAUCGUGACAGGUCAAAUUCGACACGAGCUCAAAAGGCCAGAGCCAAGCUGUUGAAGCUAUCUUCUUCGCAAUUUUACGAGCUGAGUACAGACGUGUCCGAUGAGCUGCAGAGGAGAAUCGGUGAAGAUGCUAACCAACCAGAUUACCUUUUGCCGAAGGCAAAUUUCCACAUGAAAAGGAACCAGGCUAGACAGAAACUGGCCAAUCUAUCACAAACUCGAUUUAAUGAUUUGUUGGACGAUAUCCUUUUUGAGAUCAAGAGAAGAGGGUUCGACAAGGAUUUGGAUGCUCCACGGCCCCCAUUACCGCAGCCGAUGAAACAAGAGGUCAGCAAAGACAGCGAUGAUACUGCAAGAACAUCCACAAAUUCUUCCUCUGUGACUCAAGUAGCUCCAAACGUCUCCGUACAACCUUCUUUGGUCAUUCCUAAGAUGGCAUCUAUCGAUUGGUCUUCUGAGGAAGAAGAAGAGGAGCAAGUAAAGGAGAAGCCAAAUGAACCGGAGGGAAAACAAACAAGCAUGGAUGAAAAGAAAGAGGCUAAACCUGCUCUAAACCCCAUAGUUACAGAUUCUGAUCUGCCUGACUCCCAAGUGCUCGCUCGUGAUAUCACAUCAAUGGCAAGGACUCCAACAACGACGCAUAAAAAUUACUGGGACGUUAAUGAUUCUCCAAUUAUCAAGGUAGAUAAAGAUAUCGAUAACGAAAAGGGUCCCGAACAGUUGAAGAGCCCUGAAGUACAACGGGCUGAGAACAAUAACCCUAACUCAGAGAUGGAAGACAAGGUUAAAGAACUGACUGAUUUAAACAGCGACUUACAUUUGCAAAUUGAAGAUUUGAAUGCUAAGUUAGCAUCUUUAACCAGCGAGAAGGAAAAGGAGAAGAAGGAAGAGAAGGAGGAAAAAGAAAAGGAAAAGAACUUAAAGAUUAACUACACCAUUGAUGAAAGUUUUCAGAAAGAAUUGCUGUCAUUAAACUCUCAAAUCGGUGAAUUAUCAAUUGAGAAUGAAAAUUUGAAGCAGAAAAUUUCAGAAUUCGAACUGCAUCAAAAAAAGAAUGACAACCAUAAUGAUUUGAAAAUCACUGACGGUUUUAUUAGCAAGUACUCUUCUGCCGAUGGGCUCAUUCCAGCUCAAUACAUCUUAAACGCUAACAACUUGAUAAUUCAAUUUACUACUAGGCUUUCCGCAGUACCCAUAGGCGACUCCACGGCAAUUUCCCAUCAAAUUGGCGAAGAGUUAUUUCAAAUAUUAUCCCAGUUAUCGAACCUAAUCUCCCAGCUAUUACUAUCGGCCGACCUAUUACAGUACAAAGAUCAGGUCAUUUUACUGAAGGCAUCAUUAUCGCAUGCGAUCACAUCGAUAAGAUAUUUCUCUGUUUACGGUCCCGUAUUAAUUCCGAAAAUAACUGUGCAAGCUGCUGUUUCAGAGGUUUGUUUUGCCAUGUGUAAUCUAAUUGAUUCAGCGAAAAUAAAAUCCGAUUCAAAUGGUGAGAGCACCACCUCUAAUGAAGGUAACCGACAGGUAUUAGAAUAUUCUUCACCAACUGCUACCACCCCAAUGACGCCAACUUUCCCCUCGACUUCUGGAAUAAAUAUGAAGAAGGGGUUUAUAAACCCAAGAAAACCAGCAUCUUUCUUGAAUGAUGUGGAGGAAGAAGAAUCUCCAGUCAAGCCAUUGAAAAUUACACAAAAGGCAAUUAACAGUCCGAUCAUAAGACCGUCAUCGUCUAAUGGAGUUCCAACAACCUCAAGAAAACCUUCAGGAACGGGGCUAUUUAGUUUAAUGAUUGAUUCAUCAAUUGCUAAGAAUAGCUCCCAUAAAGAGGAUAAUGAUAAAUAUGUCUCGCCCAUAAAGGCAGUAACAUCGGCCUCCAAUUCUGCAAGUAGCAAUAUUUCCGAAAUUCCUAAACUAACACUACCUCCACAAGCCAAAAUCGGUACUGUUAUUCCACCGUCAGAGAAUCAAGUUCCCAAUAUUAAAAUCGAGAAUACAGAAGAGGAUAAUAAAAGGAGUGACAUAACAAAUGAAAUCUCUGUUAAACCAACUUCUAGCAUUGCUGAUAAACUGAAACAAUUUGAGCAAAGUUCCGAAAAGAAAUCAUCACCAAAGGAAAAUCCUAUAGCAAAAGAAGAAAUGGAUUCAAAACCAAAACUAUCCAAUAAAUUUAUCACUUCAAUGAAUGAUGUGUCCACAGAUGAUUCAAGCUCUGAUGGUAACGAAAAUGACGAUGCAGACGAUGAUGAUGAUUUUACCUAUAUGGCAUUGAAACAAACAAUGAAGAGAGAAGGUUCAAAAAUUGAAAAAAAUAAUGACAGCAAACUACCUGCAAAUAUAGUGGAACUUGAUUUACAUGAGUCACCGGAGUCCGUGAAGAUUGAAUCUCCUGAAUCGAUAAAGGAAAUCACGUCAUCUGAAAUGUCUUCAGAAAUGCCAAGUAGUUCGCUGCCUAAGAGAUUAGUAGAGGAUGUUGAGCCUUCAGAAAUGCCAGAGAAGGGCGCAUCUGUAGAAUCAGUCAGGAAGAAAAAUUUUCAAGAACCACUUGGUAAUGUCGAAUCUCCGGAUAUGACGCAGAAGGUCAAGUCUUUGGGUAUGACAGGAAAGGCUGUAGGCCCAGAAUCAGAUAGUAGGGUCGAAUCUCCGGGCAUGACAGGACAGAUUAAAUCUUUGAAUAUGGCAGGAAAAGUUGUAGGCCCAGAAGCAGAUAGUAGGGUCGAAUCUCCGGGCAUGAAAGAGCAGAUUAAGUCUUUGGGUAUGACAGGAAAAAUUACAGCUCAAGAAUCAAUCAAGUCCCCGGAAGCGGCUAGGAAGUUGGCGUCAUCAGGAGAAGUUGACAAAAUUGAAUCUCCAAGAAUGGUAAGGGAAAGCGAGUCCUUGGAGGCAGUAGGCAAUACUAUCCCCUCAAACAUGACAGUGAAAAUGGAAUCCCCAAAUUUAAAGGGAAAUACUGUGUCUGAACCUCAAGAAAUAAGGAGAGACAUUGCCUCCUCAGAGCCGAUAGAGAAUGUUGACCCCCCAAAAGUACUAAAAAAGAUUGUCUUUCCAAAGGCUGUUAAUAGAACUGGAUCACCAAAAUCAGUCGAAAAGACUCCAUCUUCAGCUACACUGAAAAAGAGCGGGCUCCCAGAACCGAAUAGCCAAAUUGUUUCUCCUGAAUUGGCAAAAAAUUCACCUCUAGCACCGAUAAAGAAAAAUGUCGAGUUACGAGAAACUAAUAAACCACAUACUGAGACUAUCACUUCUGUGGAACCAACAAACAAGGAUGCCAAUACUUCUUGGAGAGACGCCGACUUAAACCGUACGAUCAAACGAGAGGAGGAGGACGAAGAUUUUGAUAGAGUGAACCACAAUAUCCAGAUCACUGGUGCAUAUACGAAAACUGGAAAAAUUGAUUAUCAUAAAAUACCUGUUGAUCGUAAAGCAAAAAGCGAAGCAGAAGUGCAUACUUCCGAGGAAGAUAUUGAUGAAUCAAAUAAUGUUAAUGGAAAAAGAGCUGAUGCCCAAAUACACAUCACUGAAAGAAAGCAUGCUUUCGUAAAUCCAACUGAAAAUUCACAGGUAAAAAAGACGAGCCACUCACCAUUUUUAAACAGUAAACCGGUUCAAUACGAGAACUCAGAGUCGAACGGCGGCAUUAACAACCACAUAAAGAUAAAAAAUACUGGAGAAACUACGGCACAUGACGAGAAACAUUAUAGUGAUGAUGAUGAUUCUAGCUAUCAAUUUGUUCCCAUGAAACAUGAAGAACAAGAACAAGAACAAAACAGAAGUGAGGAAGAGGAAAGUGAAGAUGACGAUGAAGAGGAAGAAGACAGUGAUUUUGAUGUGGAUACAUUUGACAUUGAAAAUCCGGAUAAUACACUAUCAGAGUUACUAUUGUAUUUAGAACAUCAAACAAUGGACGUCAUAUCCACGAUUCAAUCGCUUUUGACAUCGAUCAAGAAACCACAGGUGACGAAGGGUAAUUUGAGGGGAGAAUCGAAUGCAAUCAACCAAGUCAUAGGUCAAAUGGUGGACGCUACUAGCAUAUCAAUGGAGCAAAGCAGAAAUGCCAAUUUGAAGAAACACGGUGAUUGGGUGGUGCAAAGUCUAAGAGACUGUUCGCGUAGAAUGACAAUUUUGUGCCAAUUAACUGGCGAUGGAAUACUAGCGAAGGAAAAGAGCGAUCAAGAUUAUGCUGACAAAAACUUCAAACAGCGGUUGGCAGGGAUUGCGUUUGAUGUUGCCAAAUGUACAAAGGAGCUGGUAAAAACUGUAGAAGAGGCAAGUUUGAAGGACGAAAUAAAUUAUUUGAAUUCGAAGUUGAAGUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM SPA2;|5 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,Fluorescence microscopy images show cy3 labeled cln3 mRNA is not efficiently recruited into whi3-spa2 droplets.
65,PMID: 29650703,RNAPS0000064,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1_ml;|CLN3,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1 ml;|5 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and recruitment coefficients show CLN3 mRNA (5 nM) is modestly recruited into preformed Whi3 droplets made with melted BNI1 (8 µM Whi3, 5 nM BNI1) unless complement regions of CLN3 are also exposed through melting (CLN3ml).In contrast, recruitment of CLN3 ml is lost when the mRNA is mixed with oligos targeting the sequence on CLN3 with complementarity to BNI1 mRNA (CLN3 ml + oligos). Outliers are indicated with (•) marks."
66,PMID: 29650703,RNAPS0000065,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1_ml;|CLN3_ml,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1 ml;|5 nM CLN3 ml,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and recruitment coefficients show CLN3 mRNA (5 nM) is modestly recruited into preformed Whi3 droplets made with melted BNI1 (8 µM Whi3, 5 nM BNI1) unless complement regions of CLN3 are also exposed through melting (CLN3ml).In contrast, recruitment of CLN3 ml is lost when the mRNA is mixed with oligos targeting the sequence on CLN3 with complementarity to BNI1 mRNA (CLN3 ml + oligos). Outliers are indicated with (•) marks."
67,PMID: 29650703,RNAPS0000066,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201;|-,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201;|-,BNI1;|CLN3_ml;|Oligos_Blend,5862nt(1-5862);|1879nt(1-1879);|-,AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA;|-,mRNA;|mRNA;|-,Saccharomyces cerevisiae;|Homo sapiens;|-,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3;|100 nM Oligos,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Oligonucleotides (i.e., oligos) complementary to these regions were added to melted CLN3 and significantly decreased the coassembly with BNI1, restoring the formation of distinct CLN3 droplets."
68,PMID: 29650703,RNAPS0000069,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201;|-,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201;|-,BNI1;|CLN3;|Oligos_Blend,5862nt(1-5862);|1879nt(1-1879);|-,AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA;|-,mRNA;|mRNA;|-,Saccharomyces cerevisiae;|Homo sapiens;|-,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,20 µM [Whi3];|5 nM BNI1;|5 nM SPA2;|100 nM Oligos,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and quantification show SPA2 mRNA incubated with oligos to target the complement nucleotide regions of BNI1 (5 nM) is less recruited into preformed Whi3-BNI1 droplets (8 µM Whi3, 5 nM BNI1) compared to native SPA2 alone."
69,PMID: 29650703,RNAPS0000070,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201;|-,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201;|-,BNI1;|CLN3;|Oligos,5862nt(1-5862);|1879nt(1-1879);|-,AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA;|-,mRNA;|mRNA;|-,Saccharomyces cerevisiae;|Homo sapiens;|-,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1 ml;|5 nM CLN3 ml;|100 nM Oligos,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and recruitment coefficients show CLN3 mRNA (5 nM) is modestly recruited into preformed Whi3 droplets made with melted BNI1 (8 µM Whi3, 5 nM BNI1) unless complement regions of CLN3 are also exposed through melting (CLN3ml). In contrast, recruitment of CLN3 ml is lost when the mRNA is mixed with oligos targeting the sequence on CLN3 with complementarity to BNI1 mRNA (CLN3 ml + oligos). Outliers are indicated with (•) marks."
70,PMID: 30100264,RNAPS0000235,https://pubmed.ncbi.nlm.nih.gov/30100264,RNAs + protein,-,-,Saccharomyces cerevisiae RNA,-,-,total RNA,Saccharomyces cerevisiae,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43];|5 µM RNA,50 mM NaCl,"50 mM HEPES-NaOH (pH 7.5), 5% (v/v) glycerol, 5 mM DTT, 10 mM Tris, pH8, 1mM EDTA",RT,≤ 10 min,crowding agent:100 mg/ml dextran,Microscopy,solute, 
71,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG,Microscopy,solute,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
72,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:160-640 µM Pb,Microscopy,"liquid, solid","Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
73,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:10-640 µM Zn,Microscopy,liquid,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
74,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:10-640 µM Ni,Microscopy,solute,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
75,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:10-640 µM Co,Microscopy,solute,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
76,PMID: 30765518,RNAPS0000263,https://pubmed.ncbi.nlm.nih.gov/30765518,RNAs + protein,-;|-,-;|-,"sc1 G quadruplex RNA (Tsang,2019);|miR-125b",36nt;|22nt(1-22),GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG;|UCACAAGUUAGGGUCUCAGGGA,irregular RNA;|miRNA,-;|Mus musculus,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"250 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019);|500 nM miRNA125b",-,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 30 min,-,Sedimentation assay,liquid,"Cy3-labeled sc1 G quadruplex RNA (Tsang,2019) and miRNA125b are nearly completely sequestered into droplets (>90%), whereas 4EBP2 strongly partitions into the droplet (∼60%). In contrast, the free Cy3 dye and Cy3- BSA exhibit negligible partitioning."
77,PMID: 30826182,RNAPS0000269,https://pubmed.ncbi.nlm.nih.gov/30826182,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"A fusion protein construct [TDP-43]-[MBP] with TDP-43 residues 1-414 fused to MBP residues 1-396|Linker is missing|length=810aa|residues=1-414/1-396
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMMKIKTG
ARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHP
DKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPL
IAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG
ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFL
ENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFW
YAVRTAVINAASGRQTVDEALKDAQTRITK",TDP-43-MBP,-,-,"810aa(1-414,1-396)","Q13148,P02686","TDP-34:PhaSePro,DrLLPS,LLPSDB,PhaSepDB,
MBP:DrLLPS,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-a1103,http://db.phasep.pro/browse/","[9-28],[84-104],[179-194],[263-269],[296-304],[326-389],[412-422],[485-490],[749-768],[794-805],[807-807]",-,In vitro,5 µM [TDP-43]-[MBP];|0-2.5 µg RNA,150 mM NaCl,"15mM HEPES (pH 7.4), 1mM DTT",RT,> 2 h,-,Differential interference contrast microscopy,liquid,"In the absence of RNA, C-terminal MBP-tagged TDP-43 WT and 5FL formed liquid-like droplets at physiological salt concentrations that did not form in the presence of 1,6 hexanediol, which disrupts weak contacts between LCDs that drive LLPS. However, in the presence of increasing concentrations of total RNA, WT TDP-43 LLPS was inhibited in a dose-dependent manner. In contrast, the RNA-binding-deficient TDP-43 5FL species was unaffected by exogenous RNA. Upon selective cleavage of the MBP tag with TEV protease, TDP-43 WT and 5FL form solid-phase aggregate."
78,PMID: 30826182,RNAPS0000269,https://pubmed.ncbi.nlm.nih.gov/30826182,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"A fusion protein construct [TDP-43]-[MBP] with TDP-43 residues 1-414 fused to MBP residues 1-396|Linker is missing|length=810aa|residues=1-414/1-396
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMMKIKTG
ARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHP
DKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPL
IAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG
ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFL
ENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFW
YAVRTAVINAASGRQTVDEALKDAQTRITK",TDP-43-MBP,-,-,"810aa(1-414,1-396)","Q13148,P02686","TDP-34:PhaSePro,DrLLPS,LLPSDB,PhaSepDB,
MBP:DrLLPS,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-a1103,http://db.phasep.pro/browse/","[9-28],[84-104],[179-194],[263-269],[296-304],[326-389],[412-422],[485-490],[749-768],[794-805],[807-807]",-,In vitro,5 µM [TDP-43]-[MBP];|12.5-25 µg RNA,150 mM NaCl,"15mM HEPES (pH 7.4), 1mM DTT",RT,> 2 h,-,Differential interference contrast microscopy,solute,"In the absence of RNA, C-terminal MBP-tagged TDP-43 WT and 5FL formed liquid-like droplets at physiological salt concentrations that did not form in the presence of 1,6 hexanediol, which disrupts weak contacts between LCDs that drive LLPS. However, in the presence of increasing concentrations of total RNA, WT TDP-43 LLPS was inhibited in a dose-dependent manner. In contrast, the RNA-binding-deficient TDP-43 5FL species was unaffected by exogenous RNA. Upon selective cleavage of the MBP tag with TEV protease, TDP-43 WT and 5FL form solid-phase aggregate."
79,PMID: 30826182,RNAPS0000269,https://pubmed.ncbi.nlm.nih.gov/30826182,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"A fusion protein construct [TDP-43]-[MBP] with TDP-43 residues 1-414 fused to MBP residues 1-396|Linker is missing||length=810aa|residues=1-414/1-396|mutation=TDP-43 F147,149,194,229,231L
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGLGLVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVLVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRALALVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMMKIKTG
ARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHP
DKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPL
IAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG
ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFL
ENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFW
YAVRTAVINAASGRQTVDEALKDAQTRITK",TDP-43-MBP,-,-,"810aa(1-414,1-396)","Q13148,P02686","TDP-34:PhaSePro,DrLLPS,LLPSDB,PhaSepDB,
MBP:DrLLPS,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-a1103,http://db.phasep.pro/browse/","[9-28],[84-104],[179-202],[206-206],[263-269],[296-304],[326-389],[412-422],[485-490],[749-768],[794-805],[807-807]",-,In vitro,5 µM [TDP-43]-[MBP];|0-25 µg RNA,150 mM NaCl,"15mM HEPES (pH 7.4), 1mM DTT",RT,> 2 h,-,Differential interference contrast microscopy,liquid,"In the absence of RNA, C-terminal MBP-tagged TDP-43 WT and 5FL formed liquid-like droplets at physiological salt concentrations that did not form in the presence of 1,6 hexanediol, which disrupts weak contacts between LCDs that drive LLPS. However, in the presence of increasing concentrations of total RNA, WT TDP-43 LLPS was inhibited in a dose-dependent manner. In contrast, the RNA-binding-deficient TDP-43 5FL species was unaffected by exogenous RNA. Upon selective cleavage of the MBP tag with TEV protease, TDP-43 WT and 5FL form solid-phase aggregate."
80,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"1M NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
81,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:7 mM ATP/Mg,"Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
82,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,"other_molecular:5% 2,5 or 1,6-Hexanediol","Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
83,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:0.5% SDS,"Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
84,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,0.5-30 min,-,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
85,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|150ng/µl RNA,150 mM NaCl,25mM HEPES (pH 7.4),RT,> 30 min,-,"Microscopy,FRAP",liquid,"PGL-3 formed dynamic condensates with a recovery rate of 0.034±0.001 s−1 that increased in intensity and decreased in number over time, as expected for a liquid phase growing by Ostwald ripening and fusion."
86,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:7 mM ATP/Mg,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
87,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,"other_molecular:5% 2,5 or 1,6-Hexanediol","Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
88,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:0.5% SDS,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
89,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"1M NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
90,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,[meg-3]:IDR;|[PGL-3]:-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,0.5-30 min,-,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
91,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=544aa|residues=1-544
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSS",meg-3,IDR,-,544aa(1-544),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492]",In vitro,0.15 µM [meg-3-IDR];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"We found, however, that at 0.15 μM, the MEG-3 IDR does not form visible condensates even in the presence of RNA."
92,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=544aa|residues=1-544
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSS",meg-3,IDR,-,544aa(1-544),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492]",In vitro,0.15 µM [meg-3-IDR];|0.3 µM [total C. elegans RNA],"1M NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"We have shown previously that the IDR readily phase separates  in vitro at concentrations greater than 1 µM18. We found, however,  that at 0.15µM, the MEG-3 IDR does not form visible condensates  even in the presence of RNA (Fig. 5b and Supplementary Fig. 6a)."
93,PMID: 30926670,RNAPS0000282,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrG;|polyrC,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rG+poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",-,"In contrast, poly-rG is known to form G quadruplexes, and these structural elements are highly stable. Interestingly, unlike the spherical coacervates formed by complexation of each of poly-rA, poly-rC, and poly-rU with PR, the assemblies formed by poly-rG and PR peptides are characterized by an open, fractal-like network structure that is resistant to thermal denaturation at high salt concentrations."
94,PMID: 30926670,RNAPS0000283,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrA;|polyrU,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA:poly-rU=60:40],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,drug:2M-6M Urea,"Microscopy,FRAP",solid,"Addition of urea to open network assemblies helped prevent the formation of networked structures, but this did not result in droplet formation (Fig. 2D). However, thermal denaturation of the poly-rA:rU-PR assemblies followed by an annealing reaction helped convert preformed open networks into spherical assemblies."
95,PMID: 30926670,RNAPS0000283,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrA;|polyrU,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA+poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP","liquid, solid","Interestingly, when preformed PR−poly-rA and PR−poly-rU condensates/coacervates were mixed together, we did not observe the formation of filamentous structures. Instead, small spherical assemblies are observed"
96,PMID: 30926670,RNAPS0000284,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrA;|polyrC,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA+poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"Interestingly, when preformed PR−poly-rA and PR−poly-rU condensates/coacervates were mixed together, we did not observe the formation of filamentous structures. Instead, small spherical assemblies are observed"
97,PMID: 30926670,RNAPS0000285,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrU;|polyrC,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rC+poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"Interestingly, when preformed PR−poly-rA and PR−poly-rU condensates/coacervates were mixed together, we did not observe the formation of filamentous structures. Instead, small spherical assemblies are observed"
98,PMID: 30926670,RNAPS0000286,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-,-,yeast rRNA,-,-,rRNA,yeast,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [rRNA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",-,"The morphologies of the resulting condensates were dependent on the specific type of polyanion and their assembly state: Micro tubule asters or filaments provided a solid scaffold for PR re cruitment, while flexible polyanions such as total yeast RNA or polyphosphate lead to the formation of spherical droplets, in dicative of a minimization of the surface energy that is consistent with liquid−liquid phase separation driven by complex coacervation."
99,PMID: 30926670,RNAPS0000287,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-,-,Saccharomyces cerevisiae RNA,-,-,total RNA,Saccharomyces cerevisiae,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [total yeast RNA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"The morphologies of the resulting condensates were dependent on the specific type of polyanion and their assembly state: Micro tubule asters or filaments provided a solid scaffold for PR re cruitment, while flexible polyanions such as total yeast RNA or polyphosphate lead to the formation of spherical droplets, in dicative of a minimization of the surface energy that is consistent with liquid−liquid phase separation driven by complex coacervation."
100,PMID: 30981631,RNAPS0000296,https://pubmed.ncbi.nlm.nih.gov/30981631,RNAs + protein,-,-,Escherichia coli RNA,-,-,total RNA,Escherichia coli,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=294aa|residues=1-294
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,-,-,294aa(1-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,15 µM [NPM1];|50 ng/mL RNA,150 mM NaCl,"10 mM Tris, pH 7.5, 2 mM DTT",RT,> 30 min,-,"Microscopy,FRAP",liquid,"(PR)23 initially infiltrated NPM1/rRNA droplets as observed in protein only droplets. NPM1 within these droplets showed no change in mobility as compared to droplets formed in the absence of (PR)23, while the recovery time of (PR)23 increased ~2-fold between the 0.253 and 0.53 additions. Upon further titration of (PR)23, droplets dissolved, leaving rRNA/(PR)23 puncta that displayed drastically reduced recovery of (PR)23, similar to (PR)23/rRNA puncta formed in the absence of NPM1. NPM1 did associate with these puncta, but not so as to cause phase separation. Further titration of (PR)23 yielded new phase separated NPM1/(PR)23 droplets that engulfed the rRNA/(PR)23 puncta. NPM1 was excluded from the rRNA/(PR)23 puncta in phase 3 droplets and had reduced mobility compared with phase 1 and NPM1/rRNA-only droplets. (PR)23 had comparatively rapid recovery in the NPM1-containing liquid droplet regions surrounding (PR)23/rRNA puncta and significantly diminished recovery within puncta. Finally, continued titration of (PR)23 resulted in the dissolution of the reformed NPM1/(PR)23 droplets, while the rRNA/(PR)23 puncta persisted."
101,PMID: 31266957,RNAPS0000307,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[tRNA];|0.5mM[K3],-,"50 mM HEPES,pH 7.4 or 9.4",RT,-,-,Turbidity measurement,-,"We then prepared peptide solutions with transfer RNA (tRNA) or polyU RNA (Fig. 2b) at different peptide concentrations and pH values and found that the mixtures underwent phase separation when K3/R3 concentrations reached ~ 0.5 mM (Fig. 2b, c and Supplementary Fig. 2b). The condensation-transition led to the occurrence of spherical droplets that fused with each other."
102,PMID: 31266957,RNAPS0000307,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[tRNA];|1 mM[K3],-,"50 mM HEPES,pH 7.4 or 9.4",RT,-,-,Turbidity measurement,-,"Turbidity of K3 with tRNA (0.5 mg ml−1) and R3 with tRNA (0.5 mg ml−1) samples at different pH values and peptide concentrations (0.1 mM, 0.5 mM, and 1 mM). Reported turbidity values represent the average of a triplicate of measurements for each sample."
103,PMID: 31266957,RNAPS0000307,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,1 mg/ml[tRNA];|2mM[K3],0 or 30 mM NaCl,"50 mM HEPES,PH 7.4",RT,-,-,Fluorescence microscopy,-,"Turbidity of K3 with tRNA (0.5 mg ml−1) and R3 with tRNA (0.5 mg ml−1) samples at different pH values and peptide concentrations (0.1 mM, 0.5 mM, and 1 mM). Reported turbidity values represent the average of a triplicate of measurements for each sample."
104,PMID: 31266957,RNAPS0000308,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,RRASLRRASLRRASL,R3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[tRNA];|0.5mM or 1mM[R3],-,"50 mM HEPES,PH 5.4 or 7.4 or 9.4",RT,-,-,Turbidity measurement,-,"Turbidity of K3 with tRNA (0.5 mg ml−1) and R3 with tRNA (0.5 mg ml−1) samples at different pH values and peptide concentrations (0.1 mM, 0.5 mM, and 1 mM). Reported turbidity values represent the average of a triplicate of measurements for each sample."
105,PMID: 32571937,RNAPS0000399,https://pubmed.ncbi.nlm.nih.gov/32571937,RNAs + protein,-,-,Saccharomyces cerevisiae RNA,-,-,total RNA,Saccharomyces cerevisiae,RGRGGRGRGGRGRGGRGRGGRGRGG,[RGRGG]5,-,-,25aa,-,-,-,-,-,In vitro,8.9 mg/mL [Cellular RNA];|0.024mg/mL [[RGRGG]5],-,"5 mM Tris-HCl, pH 7.5",RT,-,-,"Fluorescence microscopy,Differential interference contrast microscopy",liquid,"Finally, we tested whether cellular RNA, a mixture that contains both structured and unstructured RNAs, can form vesicular assem blies. Indeed, we observed that total RNA from Saccharomyces cerevisiae can form micrometer-sized hollow condensates upon interacting with an R/G-rich polypeptide at excess RNA condi tion"
106,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",MBP-N,-,-,-,P0DTC9,-,-,-,-,In vitro,0-50 µM [ total torula yeast RNA];|50 µM [N protein],50 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,-,"Turbidity measurement,Differential interference contrast microscopy",-,"We conducted turbidity and microscopy experiments with fixed protein concentration and varying protein:RNA mass ratios in low salt conditions. In low salt conditions in the absence of RNA, there is an increase in turbidity along the formation of small, spherical droplets, suggesting that N is able to undergo LLPS even in the absence of RNA."
107,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0-50 µM [ total torula yeast RNA];|50 µM [N protein],50 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,other_molecular:+ TEV protease,"Turbidity measurement,Differential interference contrast microscopy","liquid, solute","We conducted turbidity and microscopy experiments with fixed protein concentration and varying protein:RNA mass ratios in low salt conditions. In low salt conditions in the absence of RNA, there is an increase in turbidity along the formation of small, spherical droplets, suggesting that N is able to undergo LLPS even in the absence of RNA."
108,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",MBP-N,-,-,-,P0DTC9,-,-,-,-,In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,-,"Turbidity measurement,Differential interference contrast microscopy",solute,"This increase in turbidity is coupled with the appearance of small, spherical droplets visible by microscopy Interestingly, at lower pH conditions the turbidity of the reaction increases and  persists over time as has been observed for protein aggregate or gels"
109,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,other_molecular:+ TEV protease,"Turbidity measurement,Differential interference contrast microscopy",liquid,"This increase in turbidity is coupled with the appearance of small, spherical droplets visible by microscopy Interestingly, at lower pH conditions the turbidity of the reaction increases and  persists over time as has been observed for protein aggregate or gels"
110,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",MBP-N,-,-,-,P0DTC9,-,-,-,-,In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"20 mM MES,pH 5.5",RT,20 min,-,"Turbidity measurement,Differential interference contrast microscopy",solute,"At pH 5.5, the droplets still appear spherical; however, the persistent turbidity  suggests that the droplets may be less fluid (more “gel”) in these conditions.  Consistent with this hypothesis, at lower pH conditions the assemblies no longer remain  spherical and resemble droplets that were unable to complete fusion"
111,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"20 mM MES,pH 5.5",RT,20 min,other_molecular:+ TEV protease,"Turbidity measurement,Differential interference contrast microscopy",gel,"At pH 5.5, the droplets still appear spherical; however, the persistent turbidity  suggests that the droplets may be less fluid (more “gel”) in these conditions.  Consistent with this hypothesis, at lower pH conditions the assemblies no longer remain  spherical and resemble droplets that were unable to complete fusion"
112,PMID: 32615218,RNAPS0000401,https://pubmed.ncbi.nlm.nih.gov/32615218,RNAs + protein,-,-,Escherichia coli RNA,-,-,total RNA,Escherichia coli,"sp|P54397|FKB39_DROME 39 kDa FK506-binding nuclear protein OS=Drosophila melanogaster OX=7227 GN=FK506-bp1 PE=1 SV=2
MSMFWGLNMKPERKYSQTIIKSFHISGVALDKGQEAKLYLAAEKQEYIVATVTKAIPQVA
LDLNFSKGDRIMFYTAGDASVSLLGYLHDIDSEDDEDDDQMTIENLLNSKAIKNSKKSED
DEDENESGEEDEEDTDDDSQIIEEYESFLENGEEEDDDDVDEDNEESGEEDEQDSDDSEA
EEEQPKAKVAKLSPGASAKKSGKEQNGVAKKEEAKQQQKKKEKPEAKKEQPKAKEPAKQQ
PASKDPRTITGGVKIVDQVVGKGEEAKQGKRVSVYYIGRLQSNNKTFDSLLKGKPFKFAL
GGGEVIKGWDVGVAGMKVGGKRVITCPPHMAYGARGAPPKIGPNSTLVFEVELKAVH",FKBP39,-,-,357aa(1-357),P54397,-,-,[113-251],"[89-99],[118-139],[150-184],[209-242]",In vitro,0.005-0.5 µg [RNA_Blend];|0.5 µg [FKBP39],300 mM NaCl,-,4˚C,2 min,-,Differential interference contrast microscopy,liquid,"Based on this knowledge, we decided to examine the  propensity of FKBP39 to promote phase transition in the presence of RNA. The FKBP39 was  tested in 200 µg/ml (2.5 µl total volume containing 0.5 µg of the protein) in buffer  supplemented with 300 mM NaCl. As presented in Figure 8, FKBP39 can lead to LLPS in the presence of RNA."
113,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,△95-223,-,94aa(1-94),A0A0G2K0Y1,-,-,-,"[19-55],[72-94]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solute,"Notably, however, deletion of the first N-terminal 16 aa (D1-16) still allowed binding to WT Trnp1. To test the behavior of these deletion constructs in phase separation, we produced the recombinant MBP-D1-16, MBP-D1-140 (C-term IDR), and MBP-D95-223 (N-term IDR) Trnp1 proteins and tested their LLPS capacity."
114,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,-,-,225aa(1-225),A0A0G2K0Y1,-,-,-,"[19-55],[72-126],[133-146],[166-191]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solute,"Notably, addition of dextran (used here as a crowding agent) caused formation of fibrillary solid aggregate, while RNA addition had very little effects on Trnp1 LLPS and aggregation (Fig 1E). These results indicate that Trnp1 drives phase separation and hence may play a role in the formation of MLOs."
115,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,△1-140,-,83aa(141-223),A0A0G2K0Y1,-,-,-,"[141-146],[166-191]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solid,"Notably, however, deletion of the first N-terminal 16 aa (D1-16) still allowed binding to WT Trnp1. To test the behavior of these deletion constructs in phase separation, we produced the recombinant MBP-D1-16, MBP-D1-140 (C-term IDR), and MBP-D95-223 (N-term IDR) Trnp1 proteins and tested their LLPS capacity."
116,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,△1-16,-,207aa(17-223),A0A0G2K0Y1,-,-,-,"[19-55],[72-126],[133-146],[166-191]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solid,"Notably, however, deletion of the first N-terminal 16 aa (D1-16) still allowed binding to WT Trnp1. To test the behavior of these deletion constructs in phase separation, we produced the recombinant MBP-D1-16, MBP-D1-140 (C-term IDR), and MBP-D95-223 (N-term IDR) Trnp1 proteins and tested their LLPS capacity."
117,PMID: 32627867,RNAPS0000120,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),-,YFP,-,-,-,-,-,-,-,-,In vitro,50 ng [RNA_Blend];|5 µM [Trnp1],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solid,"Notably, addition of dextran (used here as a crowding agent) caused formation of fibrillary solid aggregate, while RNA addition had very little effects on Trnp1 LLPS and aggregation (Fig 1E). These results indicate that Trnp1 drives phase separation and hence may play a role in the formation of MLOs."
118,PMID: 32649883,RNAPS0000129,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,NCBI ID:283131;|-,https://www.ncbi.nlm.nih.gov/gene/283131;|-,NEAT1;|yeast tRNA,3756nt(1-3756);|-,GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA;|tRNA,Homo sapiens;|yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,-,-,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,1.25µg/µl tRNA;|0-400ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Differential interference contrast microscopy,"liquid, solute","We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
119,PMID: 32649883,RNAPS0000129,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,NCBI ID:283131;|-,https://www.ncbi.nlm.nih.gov/gene/283131;|-,NEAT1;|yeast tRNA,3756nt(1-3756);|-,GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA;|tRNA,Homo sapiens;|yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,1.25µg/µl tRNA;|0-400ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Differential interference contrast microscopy,"liquid, solute","We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
120,PMID: 32649883,RNAPS0000129,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,NCBI ID:283131;|-,https://www.ncbi.nlm.nih.gov/gene/283131;|-,NEAT1;|yeast tRNA,3756nt(1-3756);|-,GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA;|tRNA,Homo sapiens;|yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-190,263-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSKHNSNRQLERSG",TDP-43,△RRM2,-,"202aa(1-190,263-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,1.25µg/µl tRNA;|0-400ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Differential interference contrast microscopy,liquid,"We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
121,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTED ENDEPIEIPS EDDGTVLLST VTAQFPGACG LRYRNPVSQC MRGVRLVEGI LHAPDAGWGN LVYVVNYPKD NKRKMDETDA SSAVKVKRAV QKTSDLIVLG LPWKTTEQDL KEYFSTFGEV LMVQVKKDLK TGHSKGFGFV RFTEYETQVK VMSQRHMIDG RWCDCKLPNS KQSQDEPLRS RKVFVGRCTE DMTEDELREF FSQYGDVMDV FIPKPFRAFA FVTFADDQIA QSLCGEDLII KGISVHISNA EPKHNSNRQL ERSG",TDP-43,-,protein_mutation:D169G,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,"solute, liquid","Suppression of TDP-43 LLPS by total RNAs showed no marked difference between D169G and WT TDP-431-274 (Figures 7C and 7D). In contrast, the induction of TDP-43 LLPS by NEAT1 RNA was drastically reduced by D169G (Figures 7E and 7F)."
122,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTED ENDEPIEIPS EDDGTVLLST VTAQFPGACG LRYRNPVSQC MRGVRLVEGI LHAPDAGWGN LVYVVNYPKD NKRKMDETDA SSAVKVKRAV QKTSDLIVLG LPWKTTEQDL KEYFSTFGEV LMVQVKKDLK TGHSKGFGFV RFTEYETQVK VMSQRHMIDG RWCDCKLPNS KQSQDEPLRS RKVFVGRCTE DMTEDELREF FSQYGDVMDV FIPKPFRAFA FVTFADDQIA QSLCGEDLII KGISVHISNA EPKHNSNRQL ERSG",TDP-43,-,-,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,"liquid, solute","In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
123,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,liquid,"In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
124,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|100 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,liquid,"In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
125,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-190,263-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSKHNSNRQLERSG",TDP-43,△RRM2,-,"202aa(1-190,263-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,liquid,"In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
126,PMID: 32649883,RNAPS0000411,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,-,-,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-5µg/µl tRNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Microscopy,"liquid, solute","WT and DRRM1 TDP-431-274 showed  similar sensitivity to tRNA (R1.25 mg/ml) (Figures 5E and 5F),  whereas DRRM2 required a higher concentration of tRNA  (R2.5 mg/ml) (Figure 5G)."
127,PMID: 32649883,RNAPS0000411,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-5µg/µl tRNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Microscopy,"liquid, solute","WT and DRRM1 TDP-431-274 showed  similar sensitivity to tRNA (R1.25 mg/ml) (Figures 5E and 5F),  whereas DRRM2 required a higher concentration of tRNA  (R2.5 mg/ml) (Figure 6G)."
128,PMID: 32649883,RNAPS0000411,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-190,263-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSKHNSNRQLERSG",TDP-43,△RRM2,-,"202aa(1-190,263-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-5µg/µl tRNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Microscopy,"liquid, solute","WT and DRRM1 TDP-431-274 showed  similar sensitivity to tRNA (R1.25 mg/ml) (Figures 5E and 5F),  whereas DRRM2 required a higher concentration of tRNA  (R2.5 mg/ml) (Figure 7G)."
129,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CIDR,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
130,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CTD,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
131,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△linker,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",solute,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
132,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NIDR,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
133,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTD,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
134,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/ml [torula yeast RNA];|50 µM [N protein],183 mM NaCl,50 mM Tris pH 7.4 ,RT,-,-,Differential interference contrast microscopy,liquid,"The fact that no phase separation is observed in the absence of TEV cleavage suggests that interactions at these conditions are not mediated by artifactual contacts between MBP and N, as these should be enhanced when the proteins are fused."
135,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/ml [torula yeast RNA];|50 µM [N protein],183 mM NaCl,pH 5.5,RT,-,-,Differential interference contrast microscopy,liquid,"The fact that no phase separation is observed in the absence of TEV cleavage suggests that interactions at these conditions are not mediated by artifactual contacts between MBP and N, as these should be enhanced when the proteins are fused."
136,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,12.5 µM [torula yeast RNA];|50 µM [N protein],100 mM NaCl,50 mM Tris pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"At conditions of 1:0.25 MBP-N:RNA, the turbidity of the solution and the apparent number and size of the liquid droplets are enhanced compared to without RNA (Fig 4A and C). Interestingly, at higher RNA concentrations turbidity and droplet formation are diminished"
137,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/ml [desalted totaltorula yeast RNA];|50µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N."
138,PMID: 33290746,RNAPS0000451,https://pubmed.ncbi.nlm.nih.gov/33290746,RNAs + protein,-;|-,-;|-,SARS-CoV-2 virus RNA;|SARS-CoV-2 virus RNA,996nt(13404-14400);|1000nt(1-1000),ACUGAAGUGUAUUACCAGUUAUGAAGAAAAUAGGGCAAUACUCAACACACAUAAAAACAAUACCUCUGGCCAAAAACAUGACAGUUGUAACUACACCUGAGUAGUUAGAAGUAACAGAGAUUAUAAGAGCCCACAUGGAAAUGGCUUGAUCUAAAGCAUUACCAUAAUAAACUUUAUAAACGAGUGUCAAGACAUUCAUAAGUGUCCACACUCUCCUAGCACCAUCAUCAUACACAGUUCUUGCUGUCAUAAGGAUUAGUAACACUACAGCUGAUGCAUACAUAACACAGUCUUUUAGCUUAAAACCAGACAAACUAGUAUCAACCAUAUCCAACCAUGUCAUAAUACGCAUCACCCAACUAGCAGGCAUAUAGACCAUAUUAAAAUAAGCUACAGUGGCAAGAGAAGGUAACAAAAACAAACAGAGAAAUGCAUGCUUAUGUUUGACAAACAUCAUUGCAAAAGCAGACAUAGCAAUAAUACCCAUAGCAAAAGGUAAAAAGGCAUUUUCAUACAAAAAAAAGAACAAAGACCAUUGAGUACUCUGGACUAAAACUAAAAGUGAAGUCAAAAUUGUGAGUAACAACCAGUGGUGUGUACCCUUGAUUGUUCUUUUCACUGCACUUUGGAAAGUAACACCUGAGCAUUGUCUAACAACAUCAAAAGGUGUAAAUUCAUCUUCUAAUAAAGCACUACCCAAUAUGGUACGUCCAUUCAUACCAUUUUGCAGUAAUUCUUUUAAUGAAGCACACAUAUCUAAAACGGCAAUUCCAGUUUGAGCAGAAAGAGGUCCUAGUAUGUCAACAUGGUCUUGUGUUAGAGGUUCAUAAUUGUACUUCAUAGCCACAAGGUUAAAGUCAUUAAGAGUUGUGGUAAAUCGAUUGAGAAACCACCUGUCUCCAUUUAUAACAGCAGCGUACAACCAAGCUAAAACAUUAACUGUAAUAGUUGUGUCCGUACCAGCUGCUUGUGCUGUUUGCCUGUCAACAAAAGGUC;|GGUUAAUGUUGUCUACUGUUGUAAACACCUUAAUAGUCCUCACUUCUCUCAAAGAAAGAAGUGUCUUAAGAUUGUCAAAGGUGAUAACUUCACCAUCUAGGUGGAAUGUGGUAGGAUUACUAGUGUAAUAUACACUUUUAUCACCUCUCUUAAGAAAUUCUAUACCUAGUUGUGUAGAUUGUCCAGAAUAGGACCAAUCUUUAUAGGAACCAGCAAGUGAGAUGGUUUCAAUAAAAUGUUCUUCAGGUGUUUUAGAAGAAGAAGUAAGAUAACCAUUAUACGCUGUAACAGCAUCAGGUGAAGAAACAGAAACUGUAGCUGGCACUUUGAGAGAUCUCAUAUACCGAGCAGCUUCUUCCAAAUUUAAGCCAUGUGUUACAUAGCCAAGUGGCAUUGUAACAAGAGUUUCAUUUAGAUCGUUAAGUGUGUUGAUAAGUGACGCUACAGUUGUUUUACUGGUGUAAAAGUAAAAUCUAGCACCAUAAUCAACCACACCCUCUUGUAUUUUAAUACCCUUAUAUUUACGCUGUAUAGUUGAAACUAUGGCUUUAGUUUCCACACAGACAGGCAUUAAUUUGCGUGUUUCUUCUGCAUGUGCAAGCAUUUCUCGCAAAUUCCAAGAAACAGUUCCAAGAAUUUCUUGCUUCUCAUUAGAGAUAAUAGAUGGUAGAAUGUAAAAGGCACUUUUACACUUUUUAAGCACUGUCUUUGCCUCCUCUACAGUGUAACCAUUUAAACCCUGACCCGGGUAAGUGGUUAUAUAAUUGUCUGUUGGCACUUUUCUCAAAGCUUUCGCUAGCAUUUCAGUAGUGCCACCAGCCUUUUUAGUAGGUAUAACCACAGCAGUUAAAACACCCUCUUGAACAACAUCACCCACUAUAUAUGGAGCAUCUUUCUUUAAGAAAGUGAUGUCAAUGUCACUAACAAGAGUGGCAGAAUCUGGAUGAAGAUUGCCAUUAAUGUCAAUAUAAAGUAACAAGUUUUCUGUGAGGAACUUAGU,virus RNA;|virus RNA,SARS-CoV-2 virus;|SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 nM [SARS-CoV-2 5‘end];|50 nM [SARS-CoV-2 frameshifting],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,solute,"We mixed frameshifting region RNA with either 5’ end or nucleocapsid RNA. Mixtures con taining the 5’ end and frameshifting region produced droplets of intermediate properties, including smaller size and more numerous assemblies. Similarly, frameshifting region RNA made nucleocapsid RNA condensates less flocculated and smaller"
139,PMID: 33376791,RNAPS0000454,https://pubmed.ncbi.nlm.nih.gov/33376791,RNAs + protein,-,-,Escherichia coli RNA,-,-,total RNA,Escherichia coli,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,-,238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/",-,-,In vitro,0.001-1 mg/ml [total cellular RNA];|0.001-1 mg/ml [GFP],"60 mM KCl, 40 mM NaCl",70 mM K2HPO4(pH 7.4),RT,-,-,"Turbidity measurement,Fluorescence microscopy",-,Variants with an expected net charge below +18 did not phase separate with RNA under simulated physiological conditions (Supplemen tary Figure 3). We next explored the phase boundary for each GFP variant (≥+18) that phase separated in this initial assay
140,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0-150 µM [Total HeLa cellular RNA];|0-30 µM[N protein],150 mmol/L NaCl,pH 8.0,RT,5 min,-,FRAP,"liquid, solute","Because the N protein binds to genomic RNA to participate in viral genome replication and subgenomic mRNA transcription [31], we next characterized the effect of RNA on LLPS of the N protein, found that HeLa RNA strongly promoted the N protein LLPS without impacting mCherry"
141,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△SR,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
142,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-175
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEG
",SARS-CoV-2 Nucleoprotein,1-175,-,175aa(1-175),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
143,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-210
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARM",SARS-CoV-2 Nucleoprotein,1-210,-,210aa(1-210),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
144,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|51-419
SWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,51-C,-,369aa(51-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,solute,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
145,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
146,PMID: 33762340,RNAPS0000144,https://pubmed.ncbi.nlm.nih.gov/33762340,RNAs + protein,NCBI ID:18870687;|-,https://www.ncbi.nlm.nih.gov/gene/18870687;|-,GLS1;|GIRGL,5926nt(1-5926);|-,CUUCUUUUAGUGUCGUAACAUCGAUUUAUACCUAACCAUCCAAUCCUUAUCAUCAUUGCCACUAACCACUGUCCUACCUUUUCUAAGAAAGCAGUAGUAAUAGCAAUAUAAAUAUAAGUCAGAUGUCGUAUAACGAUAAUAAUCACAAUUAUUAUGAUCCCAACCAACAGCCCAGUGGUGCUCCACUUCAGGGUGAUGGUUACUAUCAACAACCAUAUGAUGAUAUGAACCAACAACAACAAGAUUACUAUGAUCCAAAUGUUCAAUAUCAACAACAACCAUAUGAUAUGGAUGGAUACCAGGAUGGUGCCCAAUACGGUAGUCAACCUGCCCAAGGUUAUAAUGCUGAUCCAGAAGCCUUUUCUGAUUUCAGUUAUGGUGGUCAAACUCCAGGUGCUUCAUAUGAUCAAUAUGGUACCCAAUACACUCCUUCUCAAAUGAGUUAUGGUGGUGACCCAAGAUCUUCUGGUGCCUCAACUCCAAUUUAUGGAGGUCAAGGUCAAGGAUAUGAUCCAUCACAAUUCCAAAUGUCAUCUAACUUACCUUAUCCUGCUUGGUCUGCUGAUCCUCAAGCUCCAAUCAAGGUUGAGCAUAUUGAAGAUAUCUUUAUUGAUUUAACAAACAAGUUUGGUUUCCAAAGAGAUUCUAUGAGAAAUAUGUUUGAUUACUUUAUGACCUUGUUAGAUUCUAGAUCCUCAAGAAUGUCACCAGCUCAAGCACUUUUAAGUUUACACGCUGAUUAUAUUGGUGGUGAAAAUGCUAAUUAUAGAAAAUGGUUCUUUUCUUCCCAACAAGAUUUAGACGAUUCUCUCGGUUUUGCUAAUAUGGCCUUAGGUAAGAUUGGUAGAAAGGCUAGAAAAGCAUCCAAGAAGUCUAAGAAGGCAAGAAAGGCAGCCGAAGAACAUGGUGAAGAUGUUGAUGCUCUUGCUACUGAAUUAGAAGGUGAUUAUUCAUUGGAAGCUGCUGAAAUCAGAUGGAAAGCCAAGAUGAACACUUUAACUCCUGAAGAAAGAGUUCGUGAUAUUGCUCUUUACGUGUUAUUAUGGGGUGAAGCUAAUCAAGUUCGUUUUACUCCAGAAUGUUUAUGUUAUAUCUACAAGACUGCAUCUGAUUACUUGAACUCUCCAUUGUGUCAACAAAGACAAGAACCAGUUCCUGAAGGUGAUUAUUUGAACAGAGUUAUUACCCCAUUAUAUAGAUUCCUUAGAUCUCAAGUUUAUGAGAUUUACGAAGGUAAAUUCGUCAAACGUGAAAAGGAUCACAAUAAGGUUAUUGGUUAUGAUGAUGUUAAUCAAUUAUUUUGGUACCCAGAGGGUAUUUCCAGAAUCAUGUUUGAAGAUGGAACAAGAAUGGUGGAUAUUCCACAAGAAGAACGUUAUUUAAGACUUGGUGAAGUUGAAUGGAAUAAUGUAUUCUUCAAAACUUAUAAGGAAAUUAGAACUUGGUUACAUUUCAUUACUAAUUUCAAUAGAAUUUGGAUUAUCCAUGCAAGUAUUUACUGGAUGUAUACUGCUUACAACUCCCCAACCUUAUAUACCAAGAAUUACGUUCAAACCAGAAACCAACAACCUCUUGCUUCUUCAAGAUGGGCUGCUUGUGCUAUUGGUGGUGUCGUUGCUUCCCUUAUUCAAAUUUUUGCUACCCUUUUUGAAUGGAUGUUUGUUCCAAGAGAAUGGGCUGGUGCUCAACAUUUGACUCGUCGUUUAAUGUUUUUGAUUUUGAUUUUCUUUGUUAACUUGGCUCCUGUGGUUUAUACAUUCAAGAUUACUGGUUUAACAUUAUACUCCAAAUCUGCUUACGCGGUCUCAAUUGUUGGUUUCUUUAUUGCUGUUGCCACCAUUAUUUUCUUUGCCGUUAUGCCAUUGGGUGGGUUAUUCACUUCAUACAUGAACAAGAGAUCUAGAAGAUAUAUUUCAUCUCAAACUUUCACUGCUAAUUUCAUCAAGUUGAAGGGUUUGGAUAUGUGGAUGUCAUAUUUAUUAUGGUUCUUAGUUUUCCUUGCCAAGUUGGUCGAAUCUUAUUUCUUCUUGACCUUAUCUAUUAGAGAUCCUAUUAGAAUUUUGUCCACCACUACCAUGAGAUGUGUUGGUGAAGUUUGGUAUAAGGAAGCAGUUUGCAGAAACCAAGCUAAGAUUGUUUUGGGUUUGAUGUACCUUGUUGAUUUGUUAUUGUUCUUCUUGGAUACUUACAUGUGGUACAUUAUUUGUAACUGUAUCUUCUCCAUCGGUCGUUCCUUCUACUUGGGUAUUUCUAUCUUGACUCCAUGGAGAAACAUUUUCACCAGAUUGCCAAAGAGAAUCUACUCCAAGAUUUUAGCUACCACUGAAAUGGAAAUUAAGUAUAAGCCAAAGGUUUUGAUUUCCCAAAUCUGGAACGCUAUUGUGAUUUCUAUGUACAGAGAACAUUUGUUAGCCAUUGACCAUGUCCAAAAGUUAUUAUACCACCAAGUUCCUUCAGAAAUUGAAGGUAAGAGAACUUUGAGAGCUCCAACUUUCUUUGUUUCUCAAGAUGAUAACAACUUUGAAACUGAAUUCUUCCCAAGAAAUUCCGAAGCUGAAAGAAGAAUUUCUUUCUUUGCUCAAUCUUUAGCUACUCCAAUUCCAGAACCAUUACCAGUUGACAACAUGCCUACUUUUACUGUUUUCACUCCUCACUAUUCUGAAAAGAUUUUGUUAUCAUUGAGAGAAAUUAUUAGAGAAGAUGAUCAAUUCUCUAGAGUUACUUUAUUGGAAUACUUGAAACAAUUGCACCCAGUUGAAUGGGACUGUUUUGUCAAGGAUACUAAGAUUUUGGCUGAAGAAACUGCUGCCUACGAAAAUGGCGAUGAUUCCGAAAAGAUGUCUGAAGAUGGAUUGAAAUCUAAGAUUGAUGAUUUACCAUUCUACUGUAUUGGUUUCAAGUCUGCUGCCCCUGAAUAUACUUUAAGAACUAGAAUCUGGGCCUCUUUGAGAUCUCAAACUUUAUAUAGAACUGUUUCUGGUUUCAUGAAUUAUGCUAGAGCUAUCAAGUUGUUGUACAGAGUUGAAAACCCAGAAUUGGUUCAAUACUUUGGUGGCGAUCCAGAAGGUUUAGAAAUGGCUUUGGAAAAGAUGGCUAGAAGAAAGUUUAGAUUCUUGGUUUCUAUGCAAAGAUUGUCCAAGUUUAAGGAUGAUGAAAUGGAAAAUGCUGAAUUCUUGUUACGUGCUUACCCAGAUUUACAAAUUGCUUACUUAGAUGAAGAACCUGCUGAAGAAGGUGAAGACGCUAGAGUUUACUCCUCAUUGAUUGAUGGUCAUUGUGAAAUGUUAGAAAACGGAAGACGUCGUCCUAAGUUCAGAGUUCAAUUGUCUGGUAAUCCAAUUUUGGGUGAUGGUAAGUCUGAUAACCAAAAUCAUGCUGUUAUUUUCCACAGAGGUGAAUAUAUUCAAUUGAUUGAUGCUAACCAAGAUAACUAUUUGGAAGAAUGUUUGAAGAUUAGAUCUGUUUUGGCUGAAUUUGAAGAAUUGAAUGUUGAACAUGUUAACCCAUAUGCUCCAAACUUGAAGAGUGAAGAAUUGAAGGACAAAAAGGAACCUGUUGCUUUCUUGGGUGCUAGGGAAUAUAUUUUCUCUGAAAACUCUGGUGUUUUGGGUGAUGUUGCCGCUGGUAAAGAACAAACUUUUGGUACCUUGUUUGCUAGAACUUUGGCUCAAAUUGGUGGUAAAUUGCAUUAUGGUCACCCGGAUUUCUUAAAUGCUACAUUUAUGUUAACUAGAGGUGGUGUUUCUAAGGCUCAAAAGGGUUUACAUUUGAACGAAGAUAUUUAUGCUGGUAUGAAUGCUAUGAUGAGAGGUGGUAAGAUUAAGCAUUGUGAAUACUACCAAUGUGGUAAAGGUAGAGAUAUGGGUUUCGGCUCUAUUUUGAAUUUCACUACUAAGAUUGGUGCUGGUAUGGGUGAACAAAUGUUGUCCAGAGAAUACUACUACUUGUCUACUCAAUUACCAUUGGAUCGUUUCUUGUCUUUCUACUAUGGUCAUCCAGGUUUCCAUAUUAAUAACUUGUUCAUUCAAUUGUCUUUACAAGUUUUCAUUUUGGUUUUGGCUAACUUGAACUCUUUGGCUCAUGAAUCUAUUAUGUGUUCUUACAACAAGGAUGUUCCAAUUACUGAUGUUUUAUAUCCAUAUGGUUGUUACAACUUGGCUCCAGCUGUUGAUUGGGUUAGACGUUAUACUUUAUCCAUUUUCAUUGUCUUCUUUAUUUCCUUCAUCCCAUUGGUUGUUCAAGAAUUAAUUGAAAGAGGUGUUUGGAAGGCUUUCCAAAGAUUUGUUAGACAUUUCCUUUCCUUAUCACCAAUGUUUGAAGUUUUCGUUGCCCAAAUCUAUUCUUCAUCUGUUUUCACUGAUUUAACUGUUGGUGGUGCUAGAUAUAUUUCCACUGGUAGAGGUUUUGCCACUUCAAGAAUCCCAUUUUCAAUUUUGUACUCCCGUUUUGCUGAUUCUUCUAUUUACAUGGGUGCAAGAUUGAUGUUGAUUUUAUUAUUCGGUAGUGUUUCUAAAUGGCAAGCUCCAUUAUUGUGGUUCUGGGCUUCAUUGUCAUCAUUGAUGUUUUCACCAUUUAUUUUCAACCCUCAUCAAUUUGCUUGGGAAGAUUUCUUCAUUGAUUACAGAGAUUUCAUUAGAUGGUUAUCCAGAGGUAAUACCAAGUGGCACAGAAACUCAUGGAUUGGUUACAUUAGACUUUCUAGAUCUCGUGUUACUGGUUUCAAGAGGAAGAUGAUUGAUGAUAUUUCUGAAAAGUCUGCUGGUGAUGCAUCCAGAGCUCACAGAUCCAACAUCUUGUUUGCUGAUUUCAUUCCAUGUCUUCUUUACACUGCUGGUCUUUAUGUUGCCUUUGUUUUCAUUAAUGCCCAAACUGGGGUUACUGAAUAUCCAUAUGAAAUUUUGGGUUCUAGAAGGCCACAACCAGUCAAUGCUACUUUGAGAGUUGUUAUUUGUGCAUUAGCUCCUGUUGUUAUUGACAUGGGUAUUUUAGCUGUCUGUGUUGCCAUGGCCUGUUGUGCUGGUCCAAUGUUGGGUAUGUGUUGCAAGAAGACUGGUGCUGUUAUUGCUGGUGUUGCCCAUGGUGGUGCUGUCAUUGUUCACAUUGUUUUCUUUAUUGUCAUGUGGGUCUUGGAAGGUUUCAACUUUGCCAGAUUAUUAUUAGGAUUUGCCACUAUGAUUUACAUUCAAAGAUUAUUAUUCAAGUUUUUAACCUUGUGUUUCUUGACUAGAGAAUUCAAGAACGAUAAGGCCAACACUGCCUUCUGGACUGGUAAGUGGUAUAACACUGGUAUGGGAUGGAUGGCUUUCACUCAACCAUCUCGUGAAUUUGUUGCCAAGAUUAUUGAAAUGUCUGAAUUUGCCGGUGAUUUCGUAUUGGCUCAUAUCAUUUUAUUCUGUCAAUUACCAGUGUUGUGUAUUCCAUUGAUUGACAGAUGGCACUCUACUAUGUUAUUCUGGUUGAAACCAUCUAGAUUGAUUAGACCACCAAUUUACUCAUUGAAGCAAGCUAGAUUAAGAAAGAGAAUGGUUAGAAAAUACUGUACAUUAUACUUUGCCAUUUUGGUAUUAUUUGUUGUUAUUAUUGUUGCCCCAGCUGUUGGUUCCAGUCAAGUUGCUGUUGAUCAAUUUGCUAACAUUGGUGGUAAUGGAUCUAUCAUCAAUGGUUUGUUCCAACCAAGAAACAUCAGUAACAACGAUACUGGUCCAAACAGACCUAAAUCAUACACCUGGUCUUAUUUCAGUACUCCAGAAAAGGGUAAGACCAAGGGUUAUUCUACCAACCCAUUCUAGAGUAUUGGUUUAAAAAAAGAUGUGUAUCAUUAGAUAUUUUUGUUGCCGAUUAUCAUUUAACAUUUUGUUUAUUUUGUUUAUACAAGUUCUUUAUAUACUUUUUUUUAUAUUAAAUUCAUGGAUUAUUACUGUUAACU;|-,mRNA;|lncRNA,Spathaspora passalidarum;|Homo sapiens,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,0.2 µM [GLS1];|0.2 µM [GIRGL];|20 µM [CAPRIN1],30 mM NaCl,"25 mM Na2HPO4(pH 7.4), 2 mM DTT",RT,-,-,Epifluorescence microscopy,liquid,"Formation of the CAPRIN1-containing condensates was dependent on the concentration of 3'UTR-1 GLS1 mRNA (fig. S5N), and moreover, these droplets were observed to undergo fusion events (fig. S5O), characteristic of protein droplets formed by liquid-liquid phase separation. Notably, the frequency of phase droplet formation between CAPRIN1 and GLS1 mRNA was comparatively increased when full-length sense, but not antisense, GIRGL was added to these assays."
147,PMID: 33479219,RNAPS0000540,https://pubmed.ncbi.nlm.nih.gov/33479219,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE",SARS-CoV-2 Nucleoprotein,-, ,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,2.5-40 µM [SARS-CoV-2 N protein];| 6.25 ng/µL [total RNAs],50 mM NaCl,25 mM HEPES pH 7.5,RT,15-30 min,-,Confocal microscopy,liquid,"Considering the ability of N protein to bind RNAs, we added total RNAs extracted from HeLa cells into N protein solutions. Droplets appeared with the supplement of RNAs (Fig.1i). Moreover, the size of condensates increased with higher protein concentration meanwhile their numbers decreased (Fig.1i)."
148,PMID: 33479219,RNAPS0000540,https://pubmed.ncbi.nlm.nih.gov/33479219,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-174
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-, ,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,10 µM [SARS-CoV-2 N protein];|0-50 ng/µL [total RNAs],50 mM NaCl,25 mM HEPES pH 7.5,RT,15-30 min,-,Confocal microscopy,"liquid, gel, solid","Next, with protein concentration fixed at 10 μΜ along with an increasing RNA gradient, we observed that N protein condensed into droplets, then gel structure and finally solid-like entanglement (Fig. 1j), suggesting RNAs play a crucial role in this process."
149,PMID: 33650968,RNAPS0000592,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:1994,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/1994,CD47;|ELAVL1,4194nt(3'UTR);|4909nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|-,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|CD47 3'UTR;|ELAVL1 3'UTR,"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Therefore, we tested whether two RNAs co-localize in the network. Labeling of several pairs of RNAs with two different fluorescent dyes showed that they colocalize"
150,PMID: 33650968,RNAPS0000593,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:8600,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/8600,CD47;|TNFSF11,4194nt(3'UTR);|1095nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGC,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|CD47 3'UTR;|TNFSF11 3'UTR,"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Therefore, we tested whether two RNAs co-localize in the network. Labeling of several pairs of RNAs with two different fluorescent dyes showed that they colocalize"
151,PMID: 33650968,RNAPS0000594,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:51311,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/51311,CD47;|TLR8,4194nt(3'UTR);|1003nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|CUGACGUUAAGUCAUGAUUUCGCGCCAUAAUAAAGAUGCAAAGGAAUGACAUUUCUGUAUUAGUUAUCUAUUGCUAUGUAACAAAUUAUCCCAAAACUUAGUGGUUUAAAACAACACAUUUGCUGGCCCACAGUUUUUGAGGGUCAGGAGUCCAGGCCCAGCAUAACUGGGUCCUCUGCUCAGGGUGUCUCAGAGGCUGCAAUGUAGGUGUUCACCAGAGACAUAGGCAUCACUGGGGUCACACUCAUGUGGUUGUUUUCUGGAUUCAAUUCCUCCUGGGCUAUUGGCCAAAGGCUAUACUCAUGUAAGCCAUGCGAGCCUCUCCCACAAGGCAGCUUGCUUCAUCAGAGCUAGCAAAAAAGAGAGGUUGCUAGCAAGAUGAAGUCACAAUCUUUUGUAAUCGAAUCAAAAAAGUGAUAUCUCAUCACUUUGGCCAUAUUCUAUUUGUUAGAAGUAAACCACAGGUCCCACCAGCUCCAUGGGAGUGACCACCUCAGUCCAGGGAAAACAGCUGAAGACCAAGAUGGUGAGCUCUGAUUGCUUCAGUUGGUCAUCAACUAUUUUCCCUUGACUGCUGUCCUGGGAUGGCCUGCUAUCUUGAUGAUAGAUUGUGAAUAUCAGGAGGCAGGGAUCACUGUGGACCAUCUUAGCAGUUGACCUAACACAUCUUCUUUUCAAUAUCUAAGAACUUUUGCCACUGUGACUAAUGGUCCUAAUAUUAAGCUGUUGUUUAUAUUUAUCAUAUAUCUAUGGCUACAUGGUUAUAUUAUGCUGUGGUUGCGUUCGGUUUUAUUUACAGUUGCUUUUACAAAUAUUUGCUGUAACAUUUGACUUCUAAGGUUUAGAUGCCAUUUAAGAACUGAGAUGGAUAGCUUUUAAAGCAUCUUUUACUUCUUACCAUUUUUUAAAAGUAUGCAGCUAAAUUCGAAGCUUUUGGUCUAUAUUGUUAAUUGCCAUUGCUGUAAAUCUUAAAAUGAAUGAAUAAAAAUGUUUCAUUUUACAA,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|CD47 3'UTR;|TLR8 3'UTR,"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Therefore, we tested whether two RNAs co-localize in the network. Labeling of several pairs of RNAs with two different fluorescent dyes showed that they colocalize"
152,PMID: 33650968,RNAPS0000595,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:919;|NCBI ID:8600;|NCBI ID:10186,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/919;|https://www.ncbi.nlm.nih.gov/gene/8600;|https://www.ncbi.nlm.nih.gov/gene/10186,CD47;|CD274;|TNFSF11;|LHFPL6,4194nt(3'UTR);|2705nt(3'UTR);|1095nt(3'UTR);|1044nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|-;|GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGC;|GAUGGAGCUACCAAGAGCAGACAGAGGAGAAGAUGGGCCAAAGGGGCUUGGAGAGGUCAAAACAUCCACCUACCUUCAAAAGGUGGGAUAGUAGUUCUAAUCCAAUACAAUGCUAAUAAAAUGAAACCCGAUAAAAUCAGGAACAUGAUAUAGGAAGGAAGGAUUGUAGGAGAUUUGUGGGGGAAAAAAAAGGAGAGUAUAGAAUGAUGGAGAAAAAUGGACCAAAGGCUAAAAAUAUUGCAGGGCAUCGGGUGUUUCUAUUCCACAGAGUAUUGUUAAUGUACAACACACACACACACACACACACACACACACACACACACACACACACAACAAAUCUACAUAUACAAACAAGGGUUUGGGUUUUAGUUUUUUUUUUUUAAGGUGAGGACUCAGAAAAUCAAAGGGCUAGUAGAAACAGUGUUAUGUUGGGAAGCAGGGUACCCCCAAAGAUGUUCCCUGUAGGUCACGGCACUCCCAAAAGCACACAAGCACAUACAGACAUAUGCAUCCCCACACACGCCUAUGCACAAACGUGGAUUAUCGCACAGACUGGGAGGUUUAGUGGUGCAUUUCUCCUCUGUUUUCUUUUUAAUAUACAUUUAAAAUACAGUAUUAUCACUUUAUAAAACAUACAUUAAGCCUAAUAAAUGGACCAAUAAGCCAAACUAUCAGUAUUUUGUAUAUCCUGCAUAAACUCUAAUUUAGUUCCUCAACAUAUUUUCAGUGUUUAUGCAGACCUUUAGAGUUAAGCCUUUGUAUUUCCAUGUUAUUCCACAAUAUGCAAUAUUUCUCUGAGUAGCUUCUGCUAUGAUAUUCUUAUGAAGAAAAGGGGCAACUUUCUGUCCACUAUAGGAGAGAAUUCAGCCGAAGAUAUGAGAGUAAUGAGAGACAUUUUCCAGUCAUUGGAUCGUGUUUUCUUUUGUCCAUUAUUGUACUGUGCUGUACCACAUUUAUUUCUAUAUUCAUUUUGUAAAAAAUUUAAAAGUGCUAUUUUGUUUGUAUUUGAAAAUCUCUGUGAAUAAAUUCUCUCUUUGAUCAAUA,mRNA;|mRNA;|mRNA;|mRNA,Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|3nM[CD47 3'UTR];|3nM[CD274 3'UTR];|50nM[TNFSF11 3'UTR];|50nM[LHFPL6 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Furthermore, the mixing of suboptimal amounts of four network-forming RNAs, together with FUS-TIS, resulted in network formation, indicating that the different RNAs have an additive effect"
153,PMID: 33650968,RNAPS0000596,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:1994;|NCBI ID:29126;|NCBI ID:960;|NCBI ID:54621;|NCBI ID:1812;|NCBI ID:10186;|NCBI ID:8600;|NCBI ID:27075;|NCBI ID:127018,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/1994;;|https://www.ncbi.nlm.nih.gov/gene/29126;|https://www.ncbi.nlm.nih.gov/gene/960;|https://www.ncbi.nlm.nih.gov/gene/54621;|https://www.ncbi.nlm.nih.gov/gene/1812;|https://www.ncbi.nlm.nih.gov/gene/10186;|https://www.ncbi.nlm.nih.gov/gene/8600;|https://www.ncbi.nlm.nih.gov/gene/27075;|https://www.ncbi.nlm.nih.gov/gene/127018,CD47;|ELAVL1;|CD274;|CD44;|VSIG10;|DRD1;|LHFPL6;|TNFSF11;|TSPAN13;|LYPLAL1,4194nt(3'UTR);|4909nt(3'UTR);|2705nt(3'UTR);|3069nt(3'UTR);|3046nt(3'UTR);|1723nt(3'UTR);|1044nt(3'UTR);|515nt(3'UTR);|1045nt(3'UTR);|1130nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|-;|-;|CACCUACACCAUUAUCUUGGAAAGAAACAACCGUUGGAAACAUAACCAUUACAGGGAGCUGGGACACUUAACAGAUGCAAUGUGCUACUGAUUGUUUCAUUGCGAAUCUUUUUUAGCAUAAAAUUUUCUACUCUUUUUGUUUUUUGUGUUUUGUUCUUUAAAGUCAGGUCCAAUUUGUAAAAACAGCAUUGCUUUCUGAAAUUAGGGCCCAAUUAAUAAUCAGCAAGAAUUUGAUCGUUCCAGUUCCCACUUGGAGGCCUUUCAUCCCUCGGGUGUGCUAUGGAUGGCUUCUAACAAAAACUACACAUAUGUAUUCCUGAUCGCCAACCUUUCCCCCACCAGCUAAGGACAUUUCCCAGGGUUAAUAGGGCCUGGUCCCUGGGAGGAAAUUUGAAUGGGUCCAUUUUGCCCUUCCAUAGCCUAAUCCCUGGGCAUUGCUUUCCACUGAGGUUGGGGGUUGGGGUGUACUAGUUACACAUCUUCAACAGACCCCCUCUAGAAAUUUUUCAGAUGCUUCUGGGAGACACCCAAAGGGUGAAGCUAUUUAUCUGUAGUAAACUAUUUAUCUGUGUUUUUGAAAUAUUAAACCCUGGAUCAGUCCUUUGAUCAGUAUAAUUUUUUAAAGUUACUUUGUCAGAGGCACAAAAGGGUUUAAACUGAUUCAUAAUAAAUAUCUGUACUUCUUCGAUCUUCACCUUUUGUGCUGUGAUUCUUCAGUUUCUAAACCAGCACUGUCUGGGUCCCUACAAUGUAUCAGGAAGAGCUGAGAAUGGUAAGGAGACUCUUCUAAGUCUUCAUCUCAGAGACCCUGAGUUCCCACUCAGACCCACUCAGCCAAAUCUCAUGGAAGACCAAGGAGGGCAGCACUGUUUUUGUUUUUUGUUUUUUGUUUUUUUUUUUUGACACUGUCCAAAGGUUUUCCAUCCUGUCCUGGAAUCAGAGUUGGAAGCUGAGGAGCUUCAGCCUCUUUUAUGGUUUAAUGGCCACCUGUUCUCUCCUGUGAAAGGCUUUGCAAAGUCACAUUAAGUUUGCAUGACCUGUUAUCCCUGGGGCCCUAUUUCAUAGAGGCUGGCCCUAUUAGUGAUUUCCAAAAACAAUAUGGAAGUGCCUUUUGAUGUCUUACAAUAAGAGAAGAAGCCAAUGGAAAUGAAAGAGAUUGGCAAAGGGGAAGGAUGAUGCCAUGUAGAUCCUGUUUGACAUUUUUAUGGCUGUAUUUGUAAACUUAAACACACCAGUGUCUGUUCUUGAUGCAGUUGCUAUUUAGGAUGAGUUAAGUGCCUGGGGAGUCCCUCAAAAGGUUAAAGGGAUUCCCAUCAUUGGAAUCUUAUCACCAGAUAGGCAAGUUUAUGACCAAACAAGAGAGUACUGGCUUUAUCCUCUAACCUCAUAUUUUCUCCCACUUGGCAAGUCCUUUGUGGCAUUUAUUCAUCAGUCAGGGUGUCCGAUUGGUCCUAGAACUUCCAAAGGCUGCUUGUCAUAGAAGCCAUUGCAUCUAUAAAGCAACGGCUCCUGUUAAAUGGUAUCUCCUUUCUGAGGCUCCUACUAAAAGUCAUUUGUUACCUAAACUUAUGUGCUUAACAGGCAAUGCUUCUCAGACCACAAAGCAGAAAGAAGAAGAAAAGCUCCUGACUAAAUCAGGGCUGGGCUUAGACAGAGUUGAUCUGUAGAAUAUCUUUAAAGGAGAGAUGUCAACUUUCUGCACUAUUCCCAGCCUCUGCUCCUCCCUGUCUACCCUCUCCCCUCCCUCUCUCCCUCCACUUCACCCCACAAUCUUGAAAAACUUCCUUUCUCUUCUGUGAACAUCAUUGGCCAGAUCCAUUUUCAGUGGUCUGGAUUUCUUUUUAUUUUCUUUUCAACUUGAAAGAAACUGGACAUUAGGCCACUAUGUGUUGUUACUGCCACUAGUGUUCAAGUGCCUCUUGUUUUCCCAGAGAUUUCCUGGGUCUGCCAGAGGCCCAGACAGGCUCACUCAAGCUCUUUAACUGAAAAGCAACAAGCCACUCCAGGACAAGGUUCAAAAUGGUUACAACAGCCUCUACCUGUCGCCCCAGGGAGAAAGGGGUAGUGAUACAAGUCUCAUAGCCAGAGAUGGUUUUCCACUCCUUCUAGAUAUUCCCAAAAAGAGGCUGAGACAGGAGGUUAUUUUCAAUUUUAUUUUGGAAUUAAAUACUUUUUUCCCUUUAUUACUGUUGUAGUCCCUCACUUGGAUAUACCUCUGUUUUCACGAUAGAAAUAAGGGAGGUCUAGAGCUUCUAUUCCUUGGCCAUUGUCAACGGAGAGCUGGCCAAGUCUUCACAAACCCUUGCAACAUUGCCUGAAGUUUAUGGAAUAAGAUGUAUUCUCACUCCCUUGAUCUCAAGGGCGUAACUCUGGAAGCACAGCUUGACUACACGUCAUUUUUACCAAUGAUUUUCAGGUGACCUGGGCUAAGUCAUUUAAACUGGGUCUUUAUAAAAGUAAAAGGCCAACAUUUAAUUAUUUUGCAAAGCAACCUAAGAGCUAAAGAUGUAAUUUUUCUUGCAAUUGUAAAUCUUUUGUGUCUCCUGAAGACUUCCCUUAAAAUUAGCUCUGAGUGAAAAAUCAAAAGAGACAAAAGACAUCUUCGAAUCCAUAUUUCAAGCCUGGUAGAAUUGGCUUUUCUAGCAGAACCUUUCCAAAAGUUUUAUAUUGAGAUUCAUAACAACACCAAGAAUUGAUUUUGUAGCCAACAUUCAUUCAAUACUGUUAUAUCAGAGGAGUAGGAGAGAGGAAACAUUUGACUUAUCUGGAAAAGCAAAAUGUACUUAAGAAUAAGAAUAACAUGGUCCAUUCACCUUUAUGUUAUAGAUAUGUCUUUGUGUAAAUCAUUUGUUUUGAGUUUUCAAAGAAUAGCCCAUUGUUCAUUCUUGUGCUGUACAAUGACCACUGUUAUUGUUACUUUGACUUUUCAGAGCACACCCUUCCUCUGGUUUUUGUAUAUUUAUUGAUGGAUCAAUAAUAAUGAGGAAAGCAUGAUAUGUAUAUUGCUGAGUUGAAAGCACUUAUUGGAAAAUAUUAAAAGGCUAACAUUAAAAGACUAAAGGAAACAGA;|AGAAGAGGAUGGUCCAUGGUUGUCUUGCUCUGAAAGCUUGGAGAGCUACAUUGAAGACGAGCUCUUCAUUCAGCUUUGACUCCACCUGCACCCCUGGCGGGGGCUUGCACUAACAAUGUUUGGGUCUCAGCAAAAAACAAAACCAAGCACACACAUCUUUCCUUCCAUGUAUUGAAAAACAUUGGUUUGAUUUGCUCUAAGUUUUCCCAAUGAUGUUUAAAAGCUUUGAGAAGGAAAGCUGCUUUGGUGUCUGAGGUGCCACUUCUGCUGUGAAUCCUGGCUUUAUCCAGGUUGAUCUACUGUGAUAGAUGCUGAUUUAGAGGGAACAGAGGUCAGGGAAGCACUGGGUCUUGGUGCCUUUUGCCGCUUUUUUUUUUUUUUUUUUUUUUUUUUGAGACGGAGUCUCCCUCUAUUGCCCAGGCUGGAGUGCAAUGGCACGAUCUUGGCUCACCACAACUUCUGCCUCCCAGGUUCAAGCGAUUCUCCUGCCUCAGCCACGGCACCUUGCAAAUAUCAGCUCCUUGGAACAGGUGAAGUUCCAGGUACCAAUGCCAAUCAGAGGAAGGCAGUUUGGUUCAGGCUUUGGAGUUAGAAACACCUGAAGUUGAAUCUGGGCUCUGUUGCUUCCUUCUUUCAUGGGCUAGAGCACGACUCUUUACCUCUCUCUUGGCCUCAAUUUCCUCACCUGUAAAAUAGAUGAGGAAGCUGCUCACUUAUUAUUGUCUCGUUCUGAAAGCUUGGAAAGCUACAUCGAAGAUGAGCUCUUCAUUCAGCUUUGAUUUGACCUGUACCCCUGGUGGGGGAUUGCACUGGCAACAUUUGGGUCUCAGCAAAAAAACCAAGCACACACAUCUUUCCUUCCAUUUAUUGAAAAACAUCUUUGUAAGAUCCAUUCAUUGAAAAACAUAAUCCAUUUAUUGAAAAAUAUCUUUGUAAGAUCACCUGCUAAAUAUGAAAAUCUGACUUGAAUUUGUACUCUUUAAAGUUGCGUAUCUGCUCUAGUGGGCAGGACCUAGGGCUUAAAGGGGAACUUCCUUUCUCCAUUUCUAAGAACUGGGACUCUAAAAUGAGAAGCUGGUUGUCUGAAGUAACCCUGCAGGUGUGGUUGGGGAAGGUCUGUUUUCUUGGAUGAAGGAACUAAACUAAGCAUAUCAGAGCACUGUCUUAACCAGUUUUAUUUCCCUGGAGAUAGAAUUCUUUUAAAAAGAGUUAGGGAGCUGGUAAUAGGAAGUGCCUUUCAUUAUAACUACAUUUUGCAGAGCUUCAUAUUUAUAUACAAGCCUCCUAGGUGAUACACUGUUAGCUUGCAGACUUUCCUAUGCUUCAUUUCUCCUGUUGCUUUCAAAGAAGGCAGGAGACACGUUUAAUAACGGAGUAUCUGGUGAUAAGAAUUGCUUGGGCAAACCAGCUCAUCUGGACUCUUUCUCAGUCUUGGAAGUGGGAAGAGGAAAACUUGUUUCCUUCCUGCUUCUUAAGGAUAUUCUGAGGGUACACUGAUCAAUAACACUAAAUUUGGAAUGAAAAUACCAUGUGAUGAGUUUAGCCUGCUGAUGCUUCCAGUAGAUCCUUGUAUAGUUUCAAGAUUUAAGUUUUCCGAUUUCAUAUAAAUUUCUUAAAGUCGAGGACCUUAUAAGGGUGCAAUGGAUGUUUGCUAAAUAUGAAAAACUGACUUGAAUUUGCACUCUUUAAUGUUGCGUAUCUGCUCUAGUGGGCAGGACCUAGGGCUUAAAGGGGAACUUCCUUUCUCCAAUUCUAGGAACUGGGACUCUAAAAUGAGAAGCUGGUUGUCUGAAGUAACCCUGCAGGUGUGGUUGGGGAAGGUCUGUUUUCUUGGAUGAAGGGAUUAAACUGAGCAAAUCACUAGAAGUAUGCCCUGUCCCCUGCUCAGAACACUGGGGAGCUCAAGAGUGGGCUGCAAUGUGCACCCCUCAGGAAUAGCUGUGAAUUGCAGGUCUACUGGCUUUUUGCUUUUUGUCUUUUGCUGCAAGGUACCCCACGUACUUAACCAUUCUCAACAGUGUAAAUCAGUGUCAUUUUAGAAUGAGAUACUCAGCUUGCUUCUAAAGUCACUGAAUUACUGAGUGAGUCUCUCCUUUAGAGUCUUCGGCAACCAAAUUCCAGAAUUGAAGAGUCUACUACUCAGAGGCAACAAGAUUAAAAAAAGAAAACACAAAAACUGUUGAGGUGAAAAAAAAAAAAAACCCUAGCUAGGAACACAGAGAAUGUUUUGUAGGAUCACUGGGAUAUUUUCCACAACUUCCUCUUCUCUAGCACACACAUCUGUUGAUAGGAAAUAUUUGAGGGUUUUUCCACUACCAAAUGGGAGCUUCAUGGUCCUGGUGUCAAACACUAUAAACCUUUGACCAGCUGAGCUGUGACUGCUGUCACAUAUCUGAGUCCUGUGUGCACAGUAAUAUCCUGGGUCAGGUAAAAUCCAGGUCUUCAAGUUUUAAGGAUUUUUUGAAGAAUUCGGGCUUCUUUAAGACGAUCCAUGCCCAAAUCCACAAGCUUGUUGACAGUGGAUUACAGUUUGUGUGGCAAAGUCCAAGUUGUUACACUGUGCUUUAAAAAAAAUCUUAUCUGCAUGUAUUGUUAACUUAGAGACCAUGAGAUCUAUUUAUCAGGACCAGGAAGAUACACACUUCAGGUCCAUUGCAACUGACUUUUUUCUUGUUUUUCUCAAACCCUGGUGGAGCCUGGGAAGGGGGCCUCCACAAUUCUGUGGCUUUGAUAUUAGCCCCAAUUCUCACAAGCACAUACAAGCCCCAUAAUUGCCGCAGGAAAACACAAGAUGGAAAAUUGCAAUAACCCAUGCACUGAGACUUAGAAAAUCAUCCUUACUAGGCAAAAUGUAUUAUGAUGCAAUAAGUGCCAACUGAUAUUUCUCACGUUGGGACUGGCCAGGAACUGCUGCAAAGAAAAAUAAGCAGCUCCUUCUCCAUUAUUUACAUUUUAAGAUGUGGUGGGGGGAGGUUGGGAGAAAUUAGUUCUGAGGUUAUCAUAUGCCUUUUUUAAAAGAUAAUGGAAUAAAGCUAUUUUUAAGUAA;|ACUCGCAGAUGAAUCCUGCCACACAUGCUCAUCCCAAAAGCUAGAGGAGAUUGCUCUGGGGCUUGCUAUUAAGAAACUAAGGUACGGUGAGACUCUGAGGUGUCAGGAGAGCCCUCUGCUGCUUUCCAACACACAAUUAACUCCGUUUCCAAAUACAUUCCAGUGUAUUUUCUGUGUUGUUCAUAGUCAAUCAAACAGGGACACUACAAACAUGGGGAGCCAUAAGGGACAUGUCUUUGGCUUCAGAAUUGUUUUUAGAAAUUUAUUCUUAUCUUAGGAUUUACCAAAUAGGGCAAAGAAUCAACAGUGAACAGCUUCACUUAAAAUCAAAUUUUUCUGGGAAGAAAAUGAGAUGGGUUGAGUUUGCUGUAUACAAACAGGUGCUAACACUGUUCCCAGCAAAGUUUUCAGAUUGUAAAGGUAGGUGCAUGCCUUCAUAAAUUAUUUCUAAAACAUUAAUUGAGGCUUACAGUAGGAGUGAGAAAUUUUUUUCCAGAAUUGAGAGAUGUUUUGUUGAUAUUGGUUCUAUUUAUUUAUUGUAUAUAUGGAUAUUUUUAAUUUAUGAUAUAAUAAAUAUAUAUUUAUCAUAUUUAAUAGGAUAAAUUAAUGAGUUUUAUCCAAGACCUUACAACCACAUUUCUGGCCAUUUAACUAGCACUUUAUAAGCCAAUGAAGCAAACACACAGACUCUGUGAGAUUCUAAAUGUUCAUGUGUAACUUCUAGAAACACAGCAGAAACUGAUAGAUAAGGGAAUAAAGUUGAAAUGAUUCCUUAAAAUUCAUGGACACAGAUAAAUGCAAGGUGAGAAUUGACAAAUGCUAUAAAUGCUUUCUUUUUCUGAAAAGAUUUUGAAAAAUUUAAAAAAGUAUAGCUACUACUGUGUUCAAAACGUUUUAAAUGACAAAUGACUUUCCCAGGGGAAUUUGCAGUUCUGUAAAUAUCUUAAAUAAAAGCCAACUUAAGAAGAGCCCAGCAUUAAAUUUACGAUCUUAGGUGGUAAUGAAAAGUAUAUGCUGCUUUGUAUUUAUGUAAAAUAAUUGGCCCUCUCCAUCUUUUCUCAUUUCAUGUGUCAGGUAGUUUUUCUGAACCACACAAAUGGCUUUCCUGGAGAGAGAUCUGUAGCACAGACAGUGGGUUACAGCAGCCCCACUGAGGGACCAAACUCAAACCCUGCAUUUCCAUCUUACCAGGUCAAACCAAACCAGUCAGUGGGGCUACUUUUUAUAGUGCUUUAAUCUGAAUUUAGAGCUGAUUUUUAAAGGAGUCUUUAAAUGUUAAUGGUAUACUAACUAACGAAUAGUGCCUCAUUAUCAUUCUUGAGUCAGAUACUUCUGUUGAUGGGAGAAACAGAAGAAUCCUUCCCUUUGGGUGUGUUGAGCUCCCCCAAAGCCAUCAGCAUCUCUUUUGACAAAUGCUAGUCCUUUCUCUGUGCUUUGGAAUCAGGUUCCUGCAUCAUCACCCGGACUGUAAAAAGUAUCAUAAGCCUCCCUUGCCAGAUGCCAACUCGUGGGGCAUUUCAACAGAGUUUCUUUGAAAUGUUUACAACGUAUUCUUCUUGAUAAGCAAUGAACUUAACAUUUAGAUGCAAUCCGUGAAAAGAAAAAAAAAUCUGAAAAAUAUCUCCUGCAUCAGGUCUGUGUUAUUUAUGUAUUGUGAAUGUUUUCUUAAUUUUAUUGGCUGUAUGCUUUCUUACACAUAAUAAAAAUAUUUUGUGAACUCAAA;|GAUGGAGCUACCAAGAGCAGACAGAGGAGAAGAUGGGCCAAAGGGGCUUGGAGAGGUCAAAACAUCCACCUACCUUCAAAAGGUGGGAUAGUAGUUCUAAUCCAAUACAAUGCUAAUAAAAUGAAACCCGAUAAAAUCAGGAACAUGAUAUAGGAAGGAAGGAUUGUAGGAGAUUUGUGGGGGAAAAAAAAGGAGAGUAUAGAAUGAUGGAGAAAAAUGGACCAAAGGCUAAAAAUAUUGCAGGGCAUCGGGUGUUUCUAUUCCACAGAGUAUUGUUAAUGUACAACACACACACACACACACACACACACACACACACACACACACACACAACAAAUCUACAUAUACAAACAAGGGUUUGGGUUUUAGUUUUUUUUUUUUAAGGUGAGGACUCAGAAAAUCAAAGGGCUAGUAGAAACAGUGUUAUGUUGGGAAGCAGGGUACCCCCAAAGAUGUUCCCUGUAGGUCACGGCACUCCCAAAAGCACACAAGCACAUACAGACAUAUGCAUCCCCACACACGCCUAUGCACAAACGUGGAUUAUCGCACAGACUGGGAGGUUUAGUGGUGCAUUUCUCCUCUGUUUUCUUUUUAAUAUACAUUUAAAAUACAGUAUUAUCACUUUAUAAAACAUACAUUAAGCCUAAUAAAUGGACCAAUAAGCCAAACUAUCAGUAUUUUGUAUAUCCUGCAUAAACUCUAAUUUAGUUCCUCAACAUAUUUUCAGUGUUUAUGCAGACCUUUAGAGUUAAGCCUUUGUAUUUCCAUGUUAUUCCACAAUAUGCAAUAUUUCUCUGAGUAGCUUCUGCUAUGAUAUUCUUAUGAAGAAAAGGGGCAACUUUCUGUCCACUAUAGGAGAGAAUUCAGCCGAAGAUAUGAGAGUAAUGAGAGACAUUUUCCAGUCAUUGGAUCGUGUUUUCUUUUGUCCAUUAUUGUACUGUGCUGUACCACAUUUAUUUCUAUAUUCAUUUUGUAAAAAAUUUAAAAGUGCUAUUUUGUUUGUAUUUGAAAAUCUCUGUGAAUAAAUUCUCUCUUUGAUCAAUA;|GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGC;|UGAGAAAACAAGGAAGAUUUCCUUUCGUAUUAUGAUCUUGUUCACUUUCUGUAAUUUUCUGUUAAGCUCCAUUUGCCAGUUUAAGGAAGGAAACACUAUCUGGAAAAGUACCUUAUUGAUAGUGGAAUUAUAUAUUUUUACUCUAUGUUUCUCUACAUGUUUUUUUCUUUCCGUUGCUGAAAAAUAUUUGAAACUUGUGGUCUCUGAAGCUCGGUGGCACCUGGAAUUUACUGUAUUCAUUGUCGGGCACUGUCCACUGUGGCCUUUCUUAGCAUUUUUACCUGCAGAAAAACUUUGUAUGGUACCACUGUGUUGGUUAUAUGGUGAAUCUGAACGUACAUCUCACUGGUAUAAUUAUAUGUAGCACUGUGCUGUGUAGAUAGUUCCUACUGGAAAAAGAGUGGAAAUUUAUUAAAAUCAGAAAGUAUGAGAUCCUGUUAUGUUAAGGGAAAUCCAAAUUCCCAAUUUUUUUUGGUCUUUUUAGGAAAGAUUGUUGUGGUAAAAAGUGUUAGUAUAAAAAUGAUAAUUUACUUGUAGUCUUUUAUGAUUACACCAAUGUAUUCUAGAAAUAGUUAUGUCUUAGGAAAUUGUGGUUUAAUUUUUGACUUUUACAGGUAAGUGCAAAGGAGAAGUGGUUUCAUGAAAUGUUCUAAUGUAUAAUAACAUUUACCUUCAGCCUCCAUCAGAAUGGAACGAGUUUUGAGUAAUCAGGAAGUAUAUCUAUAUGAUCUUGAUAUUGUUUUAUAAUAAUUUGAAGUCUAAAAGACUGCAUUUUUAAACAAGUUAGUAUUAAUGCGUUGGCCCACGUAGCAAAAAGAUAUUUGAUUAUCUUAAAAAUUGUUAAAUACCGUUUUCAUGAAAUUUCUCAGUAUUGUAACAGCAACUUGUCAAACCUAAGCAUAUUUGAAUAUGAUCUCCCAUAAUUUGAAAUUGAAAUCGUAUUGUGUGGCUCUGUAUAUUCUGUUAAAAAAUUAAAGGACAGAAACCUUUCUUUGUGUAUGCAUGUUUGAAUUAAAAGAAAGUAAUGGAAGAAUUGAUCGAUGAA;|AUGAAUCAAGAGUGAUUUGUUAAUGUAAGUGUAAUGUCUUUGUGAAAAGUGAUUUUUACUGCCAAAUUAUAAUGAUAAUUAAAAUAUUAAGAAAUAACACUUUCCUGACUUUUUUAUUAUUAAAAUGCUUAUCACUGUAGACAGUAGCUAAUCUUAUUAAUGAAAAACAAUAGACAAACAUCUGUGCAUAAUUUUUCAGACACAAUUCUGUAAAUAUUUGGAAACCUUUUAAGUAUUUAAACUUUUAAAUUUUUGAAAUAAAGUAUUCUAAACUAAUAUAAAUAAGGACAAUGAAAAAACAUGAAAGGACUUAGCAUAAUGUUAUUUUAUCUUUUCUACAACUUUGUUUAAAUUACCUUUCCAAAGAUAUUUGUGUUUAUGUAAUUUUCCACGGAAUAACAUUAAUACUCUAGGUUUAUAAACCGGUUUCACAUUAUUUCAUUUGAUCAUCACAAGAGCUUUGUGAAGUAAGCCGAGAAGUUGUUACUGGUAUUUAAUAAUAGCAAUAGAGGAGUUAAAGACUUUCCCACAGCUUGCAGGUCAAGACAAGAAAUUCAGGUCUCCUAAUUCUCAGUGGAGCUCUAUUUCUGUUAACCCAAAUUGCUGCUCUGUUUUAGGUCUCAAUUUCAUCUGUAAAAUGAUACUAAUAGUACUUAUCCCAUUGGAUUUUUGUUGAGAUUUAAAUAAAUAGCCAAAAGCCAAUACAUAAUAAACACUCAAUAAAGAUUAACCAUAAGGAGAGUCAUGAUCUGGUUCCAGGAAUACAUUGUUAGAUGACUGAAAAAUUGUAUUACUUCAAUGAAAAUACUAUAAAUAAUAACAUUUUCAUAUAUUAGUUGGUUCUCAUGCAUACAUAAUCUAAUUUUAUUUGAUCCUCACAACUGUUUAAGUUUUAUUAAAUAUACAUUAUCCCUAUUUGUAUAAAUAGAAUCAUACAAUACCUGCCUGCUUUCAUUCAACAAAAUUAUCAUGAGAUUUUUCCAUGUUGUGUACAUCAAUAGUUCAUCUAUUUUAUUGCUCAGUAAUAUUCCAUUGUGUGGAUGUAUCACUAUUUGUUUACACAUUCACCACUGAUAUAUAAGUUGCUUCCAGUGUGAGGCUGUUUUAAAUAAAGCUGCUAUGAAUAUUCA,mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA,Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|2nM[CD47 3'UTR];|2nM[ELAVL1 3'UTR];|2nM[CD274 3'UTR];|2nM[CD44 3'UTR];|2nM[VSIG10 3'UTR];|2nM[DRD1 3'UTR];|2nM[LHFPL6 3'UTR];|2nM[TNFSF11 3'UTR];|2nM[TSPAN13 3'UTR];|2nM[LYPLAL1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Importantly, mixing 10 mRNAs together with FUS-TIS only required 2 nM (0.7–3.2 ng/ml) of each mRNA which is substantially lower than the average mRNA expression in cells (Figure 4B). "
154,PMID: 33650968,RNAPS0000597,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:51311;|NCBI ID:4609,https://www.ncbi.nlm.nih.gov/gene/51311;|https://www.ncbi.nlm.nih.gov/gene/4609,TLR8;|MYC,1003nt(3'UTR);|476nt(3'UTR),CUGACGUUAAGUCAUGAUUUCGCGCCAUAAUAAAGAUGCAAAGGAAUGACAUUUCUGUAUUAGUUAUCUAUUGCUAUGUAACAAAUUAUCCCAAAACUUAGUGGUUUAAAACAACACAUUUGCUGGCCCACAGUUUUUGAGGGUCAGGAGUCCAGGCCCAGCAUAACUGGGUCCUCUGCUCAGGGUGUCUCAGAGGCUGCAAUGUAGGUGUUCACCAGAGACAUAGGCAUCACUGGGGUCACACUCAUGUGGUUGUUUUCUGGAUUCAAUUCCUCCUGGGCUAUUGGCCAAAGGCUAUACUCAUGUAAGCCAUGCGAGCCUCUCCCACAAGGCAGCUUGCUUCAUCAGAGCUAGCAAAAAAGAGAGGUUGCUAGCAAGAUGAAGUCACAAUCUUUUGUAAUCGAAUCAAAAAAGUGAUAUCUCAUCACUUUGGCCAUAUUCUAUUUGUUAGAAGUAAACCACAGGUCCCACCAGCUCCAUGGGAGUGACCACCUCAGUCCAGGGAAAACAGCUGAAGACCAAGAUGGUGAGCUCUGAUUGCUUCAGUUGGUCAUCAACUAUUUUCCCUUGACUGCUGUCCUGGGAUGGCCUGCUAUCUUGAUGAUAGAUUGUGAAUAUCAGGAGGCAGGGAUCACUGUGGACCAUCUUAGCAGUUGACCUAACACAUCUUCUUUUCAAUAUCUAAGAACUUUUGCCACUGUGACUAAUGGUCCUAAUAUUAAGCUGUUGUUUAUAUUUAUCAUAUAUCUAUGGCUACAUGGUUAUAUUAUGCUGUGGUUGCGUUCGGUUUUAUUUACAGUUGCUUUUACAAAUAUUUGCUGUAACAUUUGACUUCUAAGGUUUAGAUGCCAUUUAAGAACUGAGAUGGAUAGCUUUUAAAGCAUCUUUUACUUCUUACCAUUUUUUAAAAGUAUGCAGCUAAAUUCGAAGCUUUUGGUCUAUAUUGUUAAUUGCCAUUGCUGUAAAUCUUAAAAUGAAUGAAUAAAAAUGUUUCAUUUUACAA;|GGAAAAGUAAGGAAAACGAUUCCUUCUAACAGAAAUGUCCUGAGCAAUCACCUAUGAACUUGUUUCAAAUGCAUGAUCAAAUGCAACCUCACAACCUUGGCUGAGUCUUGAGACUGAAAGAUUUAGCCAUAAUGUAAACUGCCUCAAAUUGGACUUUGGGCAUAAAAGAACUUUUUUAUGCUUACCAUCUUUUUUUUUUCUUUAACAGAUUUGUAUUUAAGAAUUGUUUUUAAAAAAUUUUAAGAUUUACACAAUGUUUCUCUGUAAAUAUUGCCAUUAAAUGUAAAUAACUUUAAUAAAACGUUUAUAGCAGUUACACAGAAUUUCAAUCCUAGUAUAUAGUACCUAGUAUUAUAGGUACUAUAAACCCUAAUUUUUUUUAUUUAAGUACAUUUUGCUUUUUAAAGUUGAUUUUUUUCUAUUGUUUUUAGAAAAAAUAAAAUAACUGGCAAAUAUAUCAUUGAGCCAAAUCUUAA,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100nM[TLR8 3'UTR];|100nM[MYC 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"A phase separation experiment with FUS-TIS confirmed that the addition of the two predominantly structured 3'UTRs (TLR8 and MYC) generates sphere-like condensates, whereas the addition of RNAs capable of forming a crosslinked RNA network (D1-TLR8-D2 and D1-MYC-D2), which we call an RNA matrix, induces formation of mesh-like FUS-TIS condensates "
155,PMID: 33650968,RNAPS0000597,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:51311;|NCBI ID:4609,https://www.ncbi.nlm.nih.gov/gene/51311;|https://www.ncbi.nlm.nih.gov/gene/4609,TLR8;|MYC,-(3'UTR+ two RNA dimerization elements);|-(3'UTR + two RNA dimerization elements),-;|-,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100nM[TLR8 3'UTR];|100nM[MYC 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"A phase separation experiment with FUS-TIS confirmed that the addition of the two predominantly structured 3'UTRs (TLR8 and MYC) generates sphere-like condensates, whereas the addition of RNAs capable of forming a crosslinked RNA network (D1-TLR8-D2 and D1-MYC-D2), which we call an RNA matrix, induces formation of mesh-like FUS-TIS condensates "
156,PMID: 33762340,RNAPS0000150,https://pubmed.ncbi.nlm.nih.gov/33762340,RNAs + protein,NCBI ID:18870687;|-,https://www.ncbi.nlm.nih.gov/gene/18870687,GLS1;|GIRGL,-(3'UTR);|740nt(1-740),-;|-,mRNA;|lncRNA,Spathaspora passalidarum;|Homo sapiens,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,20µM[CAPRIN1];|0.2µM[GLS1 mRNA 3'UTR];|0.2µM[sense GIRGL],30 mM NaCl,"25 mM Na2HPO4(pH 7.4),2 mM DTT",RT,immediately ,-,FRAP,liquid,"Notably, the frequency of phase droplet formation between CAPRIN1 and GLS1 mRNA was comparatively increased when full-length sense, but not antisense, GIRGL was added to these assays."
157,PMID: 33762340,RNAPS0000154,https://pubmed.ncbi.nlm.nih.gov/33762340,RNAs + protein,NCBI ID:18870687;|-,https://www.ncbi.nlm.nih.gov/gene/18870687,GLS1;|GIRGL_antisense,-(3'UTR);|740nt(1-740),-;|-,mRNA;|lncRNA,Spathaspora passalidarum;|Homo sapiens,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,20µM[CAPRIN1];|0.2µM[GLS1 mRNA 3'UTR];|0.2µM[antisense GIRGL],30 mM NaCl,"25 mM Na2HPO4(pH 7.4),2 mM DTT",RT,immediately ,-,FRAP,liquid,"Notably, the frequency of phase droplet formation between CAPRIN1 and GLS1 mRNA was comparatively increased when full-length sense, but not antisense, GIRGL was added to these assays."
